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ABSTRACT 
 
Over a billion individuals worldwide suffer from neglected diseases. This equates to 
approximately one-sixth of the human population. These infections are often endemic in remote 
tropical regions of impoverished populations where vectors can flourish and infected individuals 
cannot be effectively treated due to a lack of hospitals, medical equipment, drugs, and trained 
personnel. The few drugs that have been approved for the treatments of such illnesses are not 
widely used because they are riddled with inadequate implications of cost, safety, drug 
availability, administration, and resistance. Hence, there exists an eminent need for the design 
and development of improved new therapeutics. Influential world-renowned scientists in the 
Consortium for Parasitic Drug Development (CPDD) have preformed extensive biological 
testing for compounds active against parasites that cause neglected diseases. These data were 
acquired through several collaborations and found applicable to computational studies that 
examine quantitative structure-activity relationships through the development of predictive 
models and explore structural relationships through docking. Both of these in silico tools can 
contribute to an understanding of compound structural importance for specific targets. The 
compilation of manuscripts presented in this dissertation focus on three neglected diseases: 
trypanosomiasis, Chagas disease, and leishmaniasis. These diseases are caused by kinetoplastid 
parasites Trypanosoma brucei, Trypanosoma cruzi, and Leishmania spp., respectively. 
Statistically significant predictive devices were developed for the inhibition of the: (1) T. brucei 
P2 nucleoside transporter, (2) T. cruzi parasite at two temperatures, and (3) two species of 
Leishmania. From these studies compound structural importance was assessed for the targeting 
of each parasitic system. Since these three parasites are all from the Order Kinetoplastida and the 
kinetoplast DNA has been determined a viable target, compound interactions with DNA were 
explored to gain insight into binding modes of known and novel compounds. 
 
INDEX WORDS: Trypanosomiasis, Leishmaniasis, Chagas Disease, Nucleoside transporter, 
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NEGLECTED DISEASES 
Worldwide, more than a billion individuals suffer from neglected diseases; yet very few 
drugs have been approved as therapeutics for these illnesses.
1-3
 The lack of therapeutic agents 
and the adverse effects of those available necessitates drug discovery efforts. Studies addressed 
in this compilation of manuscripts are for neglected diseases caused by parasites of the Order 
Kinetoplastida: (1) trypanosomiasis, caused by Trypanosoma brucei, (2) Chagas disease, caused 
by Trypanosoma cruzi, and (3) leishmaniasis, caused by species of Leishmania.  
Therapeutics  
Trypanosomiasis. The type of treatment for trypanosomiasis depends on the stage of 
infection, first or second, and subspecies of parasite.
4-7
 Suramin is used to treat T. brucei 
rhodesiense infections, while pentamidine is employed for T. brucei gambiense. Side effects of 
suramin treatment include nausea, vomiting, urticarial rash and lack of consciousness, whereas 
pentamidine’s side effects include hypotension, abdominal pain, hypersalivation, vertigo, nausea, 
and chest pain. The second stage treatments for both subspecies calls for melarsoprol, a drug that 
is highly toxic and consists of the following side effects: convulsions, fever, loss of 
consciousness, rashes, bloody stool, nausea, and vomiting, as well as myocardial damage, 
albuminuria, and hypertension. Eflornithine can also be employed to specifically treat T. brucei 
gambiense. The side effects associated with this compound include diarrhea, suppression of bone 
marrow, anaemia, and leukopenia. 
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Chagas Disease. Accepted clinical treatments for Chagas disease are Nifurtimox (Nfx) 
and Benznidazole (Bz); these compounds are not FDA approved.
7-9
 The most common side 
effects of Nfx are abdominal pain, dizziness, headache, loss of appetite, nausea, vomiting, and 
weight loss, whereas the most common side effects of Bz include gastrointestinal symptoms such 
as nausea and peripheral neuropathy. 
Leishmaniasis. Infections of Leishmania spp. result in three forms of the leishmaniasis 
disease: cutaneous, mucosal, and visceral.
3, 4, 7, 10, 11
 The preferred treatments are sodium 
stibogluconate for cutaneous and mucosal leishmaniasis and liposomal amphotericin B for 
visceral leishmaniasis. However, due primarily to the high cost of liposomal amphotericin B, 
sodium stibogluconate is commonly used to treat all three leishmaniasis disease forms. The most 
common side effect of sodium stibogluconate includes thrombophlebitis, abdominal pain, 
nausea, vomiting, anorexia, myalgia, arthralgia, and headache. The most predominant side effect 
of amphotericin B is nephrotoxicity. 
Research Approach 
Biological testing data were acquired through collaborations with world-renowned 
scientists in the Consortium for Parasitic Drug Development (CPDD). The compounds and their 
respective activities were employed for computational studies that examine: (1) quantitative 
structure-activity relationships (QSAR) through the development of predictive models and (2) 
explore structural relationships through docking.  
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Predictive Models. The QSAR of the structural and biological data acquired was assessed 
through partial least squares (PLS) regression modeling employing the biologically obtained 
activities and computationally calculated comparative molecular field analysis (CoMFA) and 
comparative molecular similarity indices analysis (CoMSIA) molecular descriptors. In general, 
QSAR-PLS studies follow these steps of progression: (1) compound input, (2) compound 
minimization, (3) compound alignment, (4) molecular descriptor calculation, and (5) regression 
model formation. 
Before QSAR-PLS predictive models can be formed, an extensive dataset of compound 
structures with biological activities must be acquired; it is important that biological activities are 
gained by the same biological assay for each compound of the dataset. Compounds employed for 
QSAR-PLS predictive modeling can consist of several diverse backbones. More diversity in a 
molecular modeling system leads to a greater range of structures applicable for prediction. 
When employing the SYBYL
12
 software environment to a dataset of compounds with 
biological activities, the Sketch Molecule menu can be opened and compounds may be drawn. 
Upon completion of a compound the Sketch Molecule menu needs to be exited and the 
compound ought to be named via the Name Molecule menu. The molecules should then undergo 
an initial minimization which can be done using the Minimize Molecule option. Examples of 
constructed and minimized structures may be viewed in Figure 1. Each named structure can then 
be placed into a constructed database through the Database Put Molecule option. 
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Subsequently to the input of all compounds into the database, possible conformations of 
structures should be assessed. This can be done through several methods including but not 
limited to: Systematic Conformational Search, Grid Search, Random Conformational Search, 
MultiSearch, and GA Conformational Search. The lowest energy conformations of compounds 
obtained ought to be further studied. To insure that compounds are in their lowest energy 
conformations these compounds may be re-minimized and moved to new databases. Figure 2 
displays three low energy structures of an arylimidamide compound. 
Compounds of similar low energy structural conformations ought to then be aligned; each 
alignment should consist of only one structural representation for each compound of the dataset. 
Alignment can be acquired in several ways including but not limited to: Fit Atoms, Match 
Atoms, Superimpose Atoms, Multifit, GALAHAD, and GASP. Examples are displayed in Figure 
3. Optimal compound alignment is essential to the construction of employable QSAR-PLS 
models.
13
  
A molecular spreadsheet ought to be constructed following alignment; this can be done 
by opening the database through the Open menu. Biological activities can then be input into the 
spreadsheet and molecular descriptors may be calculated by using the AutoFill menu of the 
spreadsheet. CoMFA and CoMSIA molecular descriptors can be calculated for QSAR-PLS 
modeling.
14
 CoMFA has become a model system for QSAR modeling methods and CoMSIA 
was developed to overcome limitations of CoMFA.
14, 15
 For CoMFA, each compound of a 
dataset is assigned interaction energies with respect to a probe atom and steric and electrostatic 
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molecular descriptors are calculated with a particular potential function; Lennard-Jones and 
Coulomb potentials, respectively.
16
 To keep the calculation energies in reasonable boundaries 
cut-off values are fixed: 5 kcal/mol for the Lennard-Jones potential and ±30 kcal/mol for the 
Coulomb potential. For CoMSIA, similarity indices are compiled for the compounds of a dataset 
at the intersections of a regularly spaced lattice.
13, 16, 17
 This is conducted with a grid and probe 
method, similar to CoMFA. In CoMSIA, a common probe is employed in a distance dependent 
approach that scans the entirety of the lattice and embeds each compound; the lattice points 
inside and outside the molecule are employed and cut-offs are not needed. Steric, electrostatic, 
hydrophobic, donor, and acceptor molecular descriptors are calculated using positive and 
negative fields acquired through similarity indices. The CoMSIA method indirectly evaluates the 
similarities of each molecule in the dataset, whereas the CoMFA method evaluates the 
compounds of the dataset through relative interaction energies dependant on molecular positions.  
PLS can then be employed to compare the biological activities of compounds to their 
respective calculated molecular descriptors; the PLS regression technique solves the linear model 
in a stepwise approach that includes every predictor variable in the model.
12
 A separate QSAR 
equation is prepared for each target property when multiple dependent variables are employed. 
The resulting coefficients are interrelated and usually differ from those that would be obtained by 
examining biological properties individually. An illustration of this regression technique can be 
viewed in Figure 4. With high-quality biological data and compound alignments as described 
above, predictive QSAR-PLS models can be acquired.  
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Docking. When receptor structures are available, useful information can be obtained 
through the docking of compounds into a binding site. Figure 5 displays the general scheme of 
FlexiDock, a genetic algorithm-based flexible docking method. Geometry optimization produces 
an initial population of compounds in complex with a receptor. Each complex consists of 
parameters that will be optimized: torsional angles, translation, and rotational angles. 
Reproduction takes place when complex populations swap coordinates, crossover, and/or exhibit 
random changes within the complex, mutation. Duplicate checking ensures that each complex is 
unique; this increases the complex population diversity. Conformational modifications are then 
made to the reproduced compounds and an evaluation function for scoring the resulting 
interaction is applied to the complex. The FlexiDock scoring function is based on the Tripos 
force field and estimates the energy of the compound, the receptor, and the complex energy. The 
score is evaluated with van der Waals and the user-selected energy terms, including electrostatic, 
torsional, constraint, and hydrogen bonding energies; lower energy in the complex state suggests 
better binding.  The crossover options that can be implemented when using Flexidock include: 
(1) successive generations, (2) the creation of new members, created via crossover and mutation, 
and (3) parents that can be selected for crossover. Fitness scores can be scaled to aid in selection. 
Manuscripts  
The published and unpublished manuscripts presented in this dissertation are a result of a 
series of studies examining neglected diseases through the employment of biological data and 
computational tools to examine respective parasites and relevant druggable targets.
18-21
 Chapters 
 8 
 
two through five represent four independent studies. Chapter two examines a highly diverse 
dataset of inhibitors for T. brucei P2 transporters. A QSAR-PLS model was acquired through this 
study and the compounds of the model were examined to gain an understanding of inhibitory 
compound structural importance for P2 transporter inhibition. Chapter three examines 
arylimidamides and their inhibitory activity against two species of Leishmania. This research 
endeavor resulted in a conservative predictive method acquired via predictive models employing 
both rigid and flexible compound alignments. Compound structural importance to activity was 
then assessed. Chapter four examines a dataset of diamidines and arylimidamides with respect to 
inhibitory activity against T. cruzi at two different temperatures. A pharmacophore was obtained 
and used to construct a predictive model. Inhibitory compound importance was then extrapolated 
from the model and assessed with respect to the pharmacophore at each temperature. Chapter 
five examines dimer polyamide compounds bound by DNA with respect to their cognate DNA 
sequences. Structural importance and mechanisms of binding were evaluated through docking 
analyses. This study provides insight into DNA-compound interactions that may be applicable 
for targeting parasites of the Order Kinetoplastida, since the DNA of these parasites has been 
identified as druggable targets.
22-24
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Figures 
 
Figure 1. Examples of compounds constructed and minimized within the molecular modeling 
software. Minimization should include an assigned Force Field, such as Tripos, and Charges, 
such as Gasteiger-Huckel. 
 
  
Construction of Compounds
Scaffold Structure 1. 
Backbone of   46 
training and all 12 
testing compounds.
Scaffold Structure 3. 
Backbone of DB1911 
and DB1945.
Scaffold Structure 2. 
Backbone of DB1881, 
DB1882 and 1910. 
1. Compounds were input into SYBYL 8.1.
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Figure 2. Possible conformations of structures can be explored through various methods.  
  
Minimized Conformation
2. Subsequent to a short molecular dynamics simulation of 1ns, each low 
energy compound was minimized to convergence employing the Tripos force 
field and Gaseiger-Huckel charges.
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Figure 3. The three-dimensional molecular structures aligned within Cartesian space. (A) The 
QSAR module of SYBYL can be employed to overlay rigid low energy structures via individual 
molecule translations and/or rotations. (B) The GALAHAD module of SYBYL can be used to 
overlay flexible or rigid molecular structures in torsional space. The identified features are color 
coded: cyan for hydrophobes, magenta for donor atoms, green for acceptor atoms and red for 
positive nitrogens. 
 
 
 
Alignment by Algorithms
3. Three-dimensional molecular structures were overlaid in Cartesian space. 
(A) The QSAR module was employed to overlay rigid low energy structures 
via individual molecule translations and/or rotations. (B) The GALAHAD 
module was used to overlay flexible molecular structures in torsional space. 
Resulting rigid conformations were then overlaid within the Cartesian space. 
(A)
(B)
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Figure 4. Partial least squares (PLS) is a regression technique that is employed to compare 
experimentally obtained activity values to compound molecular descriptors acquired from 
respective compounds. PLS results in a linear model.  
 
 
Partial Least Squares (PLS)
4. A regression technique was used 
to compare biological activity values 
to compound molecular descriptors; 
this resulted in linear models.
Molecular Descriptor 3
Molecular Descriptor 1
Molecular Descriptor 2
t1
t2
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Figure 5. FlexiDock employs genetic algorithms as global optimizers to apply methods of 
biological evolution.  
  
Reproduction
Population
Discard
Modification
Evaluation
 17 
 
 
 
 
CHAPTER 2: PREDICTIVE COMPUTATIONAL MODELS OF SUBSTRATE BINDING 
BY A NUCLEOSIDE TRANSPORTER 
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Transporters play a vital role in both the resistance mechanisms of existing drugs and 
effective targeting of their replacements. Melarsoprol and diamidine compounds similar to 
pentamidine and furamidine are primarily taken up by trypanosomes of the genus Trypanosoma 
brucei through the P2 aminopurine transporter. In standardized competition experiments with 
[
3
H]adenosine, P2 transporter inhibition constants (Ki) have been determined for a diverse 
dataset of adenosine analogs, diamidines, Food and Drug Administration-approved compounds 
and analogs thereof, and custom-designed trypanocidal compounds. Computational biology has 
been employed to investigate compound structure diversity in relation to P2 transporter 
interaction. These explorations have led to models for inhibition predictions of known and novel 
compounds to obtain information about the molecular basis for P2 transporter inhibition. A 
common pharmacophore for P2 transporter inhibition has been identified along with other key 
structural charisteristics. Our model provides insight into P2 transporter interactions with known 
compounds and contributes to strategies for the design of novel antiparasitic compounds. This 
approach offers a quantitative and predictive tool for molecular recognition by specific 
transporters without the need for structural or even primary sequence information of the transport 
protein. 
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Introduction 
Trypanosoma brucei are unicellular trypanosomal parasites that cause African sleeping
 
sickness in humans and nagana in livestock. These trypanosomes are auxotrophic for purines and 
thus rely entirely on purine supplies salvaged from the host environment. As such, T. brucei 
brucei expresses a multitude of purine nucleoside and nucleobase transporters.
1
 One of these, the 
T. brucei aminopurine P2 transporter, is unusual as a genuine nucleoside-nucleobase transporter 
in that it equally transports the nucleoside adenosine and the nucleobase adenine but has virtually 
no affinity for any other natural purines or pyrimidines.
1-3
 Yet, despite this apparent high level of 
selectivity, it has been shown that P2 also mediates cellular uptake of the Food and Drug 
Administration-approved drugs melarsoprol and pentamidine,
2, 4, 5
 the main veterinary 
trypanocides diminazene aceturate
6
 and possibly isometamidium,
7
 and various nucleoside drugs.
8
  
The unusual nature of this transporter has led to efforts to exploit it as an efficient conduit 
for novel trypanocides,
9, 10
 but this requires the identification of the exact pharmacophore as well 
as the physical limitations on size and charge distribution of the extracellular binding site of the 
transporter. From the structural similarities between known P2 substrates, it could be concluded 
early on that the so-called amidine motif of adenine, i.e. N(1)=C(6)−NH2 (see Figure 1), was 
very likely to play a major role in the high affinity interaction with the transporter.
3, 11
 However, 
quantitative information or three-dimensional models explaining the high affinity binding, by 
one transporter, of such diverse molecules as adenosine (Figure 1A),
2, 3
 stilbamidine (Figure 
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1C),
12
 melarsoprol (Figure 1F),
2, 3
 and even isometamidium (Figure 1G),
7
 have not been 
available. The apparent broad selectivity has been all the more intriguing for the highly similar 
transport efficiencies of P2 for adenosine and adenine, a most unusual feature for nucleoside 
transporters.
1
 
To construct a predictive and quantitative model of P2-substrate interactions, we 
determined the Ki values of a large number of highly diverse potential inhibitors, with affinities 
ranging over several orders of magnitude, through competition experiments with radiolabeled 
adenosine. These values and structures were then employed for a computational modeling 
approach to gain more information about the molecular basis for P2 transporter inhibition. The 
resulting model can be used to evaluate the affinity of the P2 transporter for existing and novel 
compounds in silico, potentially aiding in the development of novel and selectively targeted 
trypanocides. More important yet, this strategy allows robust three-dimensional insights into 
transporter-ligand binding while not requiring knowledge of the structure, or indeed the 
sequence, of a transporter and can be applied to any solute transport mechanism for which uptake 
or binding experiments can be routinely performed.  
Experimental Procedures 
Transport of [
3
H]Adenosine by Bloodstream Forms of T. brucei. Bloodstream forms of T. 
brucei brucei strain 427 were taken from stocks in liquid nitrogen and injected in adult female 
Wistar rats, from which they were harvested by exsanguination by cardiac puncture at peak 
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parasitaemia. Parasites were isolated from the blood by elution over a DE52 column 
(Whatman)
13
 and washed twice in assay buffer (AB: 33 mM HEPES, 98 mM NaCl, 4.6 mM 
KCl, 0.3 mM CaCl2, 0.07 mM MgSO4, 5.8 mM NaH2PO4, and 14 mM glucose, pH 7.3). Cells 
were resuspended in this buffer at approximately 10
8
 cells/ml prior to use in transport 
experiments. Cell counts were performed using a haemocytometer. Transport of [
3
H]adenosine 
(20-40 Ci/mmol; Amersham Biosciences) was performed exactly as described previously,
14
 in 
the presence of 250 M inosine to block the P1 adenosine uptake system. Briefly, 100 l of 50 
nM [
3
H]adenosine, mixed with various concentrations of nonradiolabeled test compounds, was 
added to 100 l AB containing 107 trypanosomes and incubated at room temperature for 30 s, 
within the linear phase of uptake.
3
 Uptake was terminated by the addition of 1 ml of ice-cold 
assay buffer containing 1 mM adenosine followed by immediate centrifugation through an oil 
layer to separate cells from external radiolabel. The amount of radiolabeled adenosine inside the 
cell was then determined using a scintillation counter and corrected for externally associated 
label as described previously.
14
 A plot of inhibitor concentration versus adenosine uptake rate 
(expressed as pmol(10
7
 cells
-1
s
-1
)) yielded sigmoidal curves with Hill coefficients of 
approximately −1, consistent with monophasic competitive inhibition (Prism 4.0; GraphPad). 
Inhibition constants were calculated from the EC50 values, using the Cheng-Prusoff equation as 
described previously.
12
 
Inhibitor Dataset. Compounds were acquired from several academic laboratories as well 
as purchased from various commercial sources. Their respective in vitro transport activities 
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along with the compound names and sources are shown in Supplemental Table 1 (Appendix A). 
Employing the formula pKi = −log(Ki), the Ki µM values for the 112 compounds were converted 
to corresponding pKi values. The pKi values for this training set span more than 4 log units.  
Software. All 112 compounds were constructed in silico with the SYBYL 8.1
15
 software 
package on a Fedora Core 5 Linux workstation. Compound structures were minimized to 
convergence using a conjugate gradient of 0.01 kcal/(mol Å) and a maximum of 10
4
 iterations 
employing the Tripos force field with Gasteiger-Hückel charges. A three-dimensional cubic 
lattice with 2 Å grid spacing in all directions was created to analyze compounds that were 
aligned as described below. No improvement was seen in the models when the grid spacing was 
reduced to 1 Å.
16
  
Initial Alignment. Through the implementation of the SYBYL software alignment 
modules, the compounds were three-dimensionally arranged by an initial analysis of structurally 
and chemically related atoms. Algorithm generated alignment was performed using the align 
database command, whereas the atom-to-atom alignment implemented the match feature of the 
alignment tools. The algorithm alignment took place first by employing similar backbone 
structures so that the majority of similar compounds were overlaid in the same molecular space. 
Structurally related compounds were then moved into separate databases. The compounds that 
belonged to the same structural classes, but which varied in atom types or had slight structural 
differences, were placed into respective databases and aligned to the most structurally related 
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compound using atom-to-atom alignment. Seven optimum databases of compounds resulted 
from initial alignment.  
When more rigid compound structures, consisting of a larger number of atoms, were 
selected as scaffolds for alignments a greater number of databases were created. These databases 
lacked the variation necessary to form Comparative Molecular Field Analysis (CoMFA) and 
Comparative Molecular Similarity Indices Analysis (CoMSIA) models for predictability. Also, 
when the databases were aligned by less rigid scaffolds, consisting of a smaller number of atoms, 
fewer models resulted, and the models produced were not statistically significant in terms of q
2
cv. 
The best models were obtained when compounds were aligned by the carbons of common 
compound backbones. These scaffolds for alignment were obtained from the compounds 
displayed in Figure 1: dataset A, adenine; dataset B, furamidine; dataset C, stilbamidine; dataset 
D, pentamidine; dataset E, 1,1’-(nonane-1,9-diyl)diguanidine; dataset F, melarsoprol; and dataset 
G, isometamidium. Datasets E-G are comprised of four, seven and four compounds, respectively. 
The alignment for these last three datasets can be viewed in Supplemental Figure 1 (Appendix 
A). These databases together consist of less than 8% of the total compounds. Because the 
purpose of the initial alignment was to determine the pharmacophore for the final alignment, 
only initial datasets A-D were evaluated through statistics and contour maps. All 112 compounds 
were included in the final pharmacophore models. 
Multiple Regression Analysis. CoMFA and CoMSIA Quantitative Structure-Activity 
Relationship (QSAR) models were generated for molecular databases through a Partial Least 
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Squares (PLS) multiple regression analysis with molecular descriptors as independent variables 
and the pKi values as dependent variables. Statistical significance in the form of q
2
cv was 
assessed through the leave-one-out cross-validation method. The number of components (n) was 
determined by the smallest predicted error sum of squares, a value that does not always 
correspond to the highest correlation coefficient (q
2
) value. Further statistical significance 
assessment was preformed for the final model using 10-fold cross-validation. The values 
obtained from the 10-fold cross-validation assessment are averages of ten trials implementing 
random compound selection. Column filtering did not improve the signal to noise ratio.
15
 
Molecular Descriptors. There are two CoMFA molecular descriptors. The steric van der 
Waals interaction and the electrostatic Coulombic interaction descriptors were calculated at each 
lattice intersection using a probe, an sp
3
 carbon atom with a formal +1 charge. Standard scaling 
and default energy cutoffs were employed. There are five CoMSIA molecular descriptors. Steric, 
electrostatic, hydrophobic, hydrogen bond donor and hydrogen bond acceptor descriptors were 
calculated using a standard probe: 1 Å radius, +1 charge, +1 hydrophobicity, +1 hydrogen bond 
donor, and +1 hydrogen bond acceptor. Steric descriptors are related to the third power of the 
atomic radii. Electrostatic descriptors are derived from partial atomic charges. Hydrophobic 
descriptors are derived from atom-based parameters. Hydrogen bond donor and acceptor atoms 
are derived from experimental values.  
Three-Dimensional Contour Analysis. The interactions of CoMFA and CoMSIA 
descriptors were visualized through the mapping of the product standard deviation with respect 
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to molecular descriptor values and coefficients (StDev*Coeff) at each lattice point. For the initial 
models, the default levels of contour by contribution were employed as follows: 80% for a 
favored region and 20% for a disfavored region. Data were analyzed, and a common 
pharmacophore was identified. The compounds of the final pharmacophore model were further 
analyzed through a contour by actual analysis, where the software output assisted in the 
determination of proper ranges for assigned values of favored and disfavored contour regions. 
Pharmacophore Model. Common contours for the initial QSAR models were identified 
through the analysis of favored and disfavored contour regions. The alignment of such contours 
aided in the identification of a final pharmacophore. All compounds were realigned, and the final 
models were constructed. 
Results 
As seen in Supplemental Table 1 (Appendix A), this study employs 112 compounds 
acquired from several academic and industry locations. These compounds all exhibit some level 
of inhibitory activity for the T .brucei brucei P2 transporter. For large datasets of compounds 
with known activity values, it is possible to employ computational biology to investigate the 
molecular basis of their activity in terms of structural contributions to Ki values. Predictive 
models can then be constructed, and important interactions can be identified. Because a large 
number of diverse compounds are in our database, a two-step procedure was used to establish a 
final model.  
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Initial QSAR Models. As a first step, compounds were obtained in their minimal energy 
conformation by using standard molecular mechanics energy minimization methods with the 
Tripos force field. Compound alignment by similar atoms of backbone structures initially 
separated the 112 compounds into seven databases, although the majority of the compounds 
resided in four of the sets. The datasets with the majority of compounds were used for initial PLS 
modeling. Table 1 displays the total number of compounds in each dataset, the n used in PLS, 
and the statistics for each model as follows: cross-validated q
2
 (q
2
cv), the standard error of 
estimate (SEE), the coefficient of determination (r
2
) and the F statistic. When q
2
 is greater than 
0.5, a model is said to have predictability better than chance; however, it is also important that 
the r
2
 value is near one, the SEE is small, and the F statistic is large.
15
 The r
2
 is a positive value 
between zero and one; with one being the best correlation and zero being no correlation. The 
SEE is a measure of the accuracy of the predictions. The F statistic is used in comparing the 
variance between the experimental and predicted values; a larger value indicates a more 
statistically significant model.  
The average statistics for the initial four models with CoMFA molecular descriptors are 
as follows: q
2
cv equal to 0.64; SEE equal to 0.23; r
2
 equal to 0.95; and F statistic equal to 123. 
Similarly, the average statistics for the four models with CoMSIA molecular descriptors were as 
follows: q
2
cv equal to 0.58; SEE equal to 0.26; r
2
 equal to 0.92; and F statistic equal to 130. 
Although the models with CoMFA and CoMSIA molecular descriptors were comparable, the 
ones with CoMFA molecular descriptors display better overall potential for analysis of molecular 
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descriptor contribution by contour maps. This is primarily due to the simplicity of two versus 
five molecular descriptors. 
Contour maps of CoMFA molecular descriptor contribution were generated for each 
model (Figure 2). The electrostatic interactions are shown as red and blue contours, and the steric 
interactions are displayed as green and yellow contours. Increasing partial positive charge is 
favored in blue regions, and increasing partial negative charge is favored in red regions, whereas 
increasing bulk in substituents is favored in green regions and disfavored in yellow regions. 
The red, blue, yellow, and green regions were then analyzed to find common alignment 
features of structures that are of importance for the final, combined pharmacophore alignment. 
Red regions of dataset A are in the areas above C6, below N9, and beside the imidazole ring of 
adenine, while those of datasets B-D were localized to a single location most often than not on 
the backbone structure. The red contours of datasets A-D can be aligned in several ways to one 
another; thus, this descriptor alone is not enough to find the final pharmacophore for alignment. 
The blue regions were most commonly found in areas of N(R1)=C(R2)−NH(R3), where R3 is 
usually H. The alignment was much improved with the inclusion of both the red and blue regions 
and further enhanced by the addition of the yellow and green regions. Yellow contour regions 
can be reduced by realignment of compounds into green regions. The yellow regions for dataset 
A are small in relation to all other contours, and reside near the 2’- and 3’- hydroxy groups of the 
ribose moiety. Dataset B exhibited yellow contours on both ends of the furamidine backbone, 
whereas dataset C displayed a yellow contour only at one end of the stilbamidine backbone. The 
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areas of yellow contour appear most at regions that consist of several compounds with 
substituents that are not precisely aligned, either because they differ largely in structure or 
because the backbone allows for deviations in the alignment. Dataset D consisted of yellow 
regions in the areas consisting of compounds that were longer than pentamidine and/or that did 
not align fully to the pentamidine backbone. Green regions of dataset A were shown above C6 
and next to bond C8/N9 of the adenine backbone, whereas the green contours of dataset B appear 
near and encompassing the phenyl with the most precise alignment. Datasets C consists of green 
contour near the most precise alignment of the compounds. For dataset D, green contours were 
located in areas that were not precisely aligned to the pentamidine structure. The green and 
yellow contours of dataset D both reside in areas of structural deviation; however, the green 
appears nearest the aromatic linking oxygen and the unaligned amidines.  
The identification of important structural features, described above, made it possible to 
realign all 112 compounds, primarily by the common N(R1)=C(R2)−NH(R3) structure found in 
the blue contour regions and secondarily by the other contour regions. The red regions of the 
four main datasets overlapped strongly, whereas the yellow regions of datasets B-D can be 
aligned to green regions of dataset A. The large compounds of dataset A also had to be realigned. 
Figure 3A displays the alignment of all 112 compounds with adenine displayed in purple and 
Figure 3B zooms in on the location of the adenine now with the purple displayed as transparent, 
and this clearly shows the pharmacophore alignment. 
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Final Pharmacophore Model. Aligned by the N(R1)=C(R2)−NH(R3) structure with 
respect to contour regions, as described above, compounds were then employed for PLS 
modeling. As before, CoMFA and CoMSIA models were generated and examined for statistical 
significance. The two models each consisted of 112 compounds but use different molecular 
descriptors and a different n. Although the q
2
cv values are similar, the remaining statistics are not; 
the model with CoMFA molecular descriptors achieved a higher level of confidence than the 
model with CoMSIA molecular descriptors (Table 2). To further validate these models, 10-fold 
cross-validation was performed. The q
2
10-Fold values for the models with CoMFA and CoMSIA 
molecular descriptors were 0.56 and 0.54, respectively. These values, along with the rest of the 
statistics, indicate statistical significance within each model.  
The calculated predictions of the models formed from the dataset with 112 compounds 
exhibit linear relationships with the experimental Ki values (Figure 4). Predictions from the 
model with CoMSIA molecular descriptors are somewhat scattered, especially at high affinity, 
whereas the model with CoMFA molecular descriptors produces more linear pKi predictions, 
especially for compounds with high affinity for the P2 adenosine transporter (Figure 4). The r
2
 
values for the linear relationships are 0.95 for the model with CoMFA molecular descriptors and 
0.86 for the model with CoMSIA molecular descriptors. 
These models can be further evaluated through examination of the final contour maps.  
Although it is useful to analyze models as a whole to gain information about a possible 
pharmacophore, once a pharmacophore model is obtained, much more information can be 
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gathered by evaluating the contour regions of individual compounds within the model. Because 
the model with CoMFA molecular descriptors is outperforming the model with CoMSIA 
molecular descriptors, the focus of this analysis will remain on the contours of the model with 
CoMFA molecular descriptors. As before, the steric contributions are displayed in yellow and 
green while the electrostatic contributions are shown in red and blue.  
The overall contour regions from the initial model have changed significantly with 
realignment and incorporation of all 112 compounds. These changes appear most dramatic when 
looking at individual compounds. In the initial models, each compound contributed roughly 2.8-
6.3 percent. This was due to similar compounds being aligned by a common backbone scaffold 
and their being only 16-36 compounds in each dataset; 1 in 36 is approximately 2.8 percent and 1 
in 16 is about 6.3 percent. This percent of contribution is much larger than the final model, where 
1 in 112 compounds is roughly 0.89 percent. It is also important to note that a larger quantity of 
compounds with similar backbones will have a significant effect on the contribution. Hence, 
based on initial models, the compounds with the adenosine scaffold structure should contribute 
the most. There are 36 of these compounds. Those with the pentamidine and stilbamidine 
scaffolds are similar and align to one another well within the final model. There are 32 of these 
compounds, whereas there are 29 compounds related to furamidine.  
From close observations of compound structure relationships in the form of contour 
maps, it is possible to determine where partial charge addition or subtraction to substituents 
could improve compound interactions with the P2 adenosine transporter. The evolutionary 
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process by which this model calculates predictions can be viewed through the evaluation of 
contour regions and experimentally determined Ki values (Figure 5). The Ki of 2-aminopyridine 
is 14 µM. When an amino group is added into the favorable steric and positive electrostatic 
contour regions to form 4,6-diaminopyrimidine the Ki becomes 3.2 µM. Note that the amino 
group has a partial positive charge. This amino group addition thus results in improved affinity. 
When the additional groups, which reside in even more favorable contour regions, are added to 
the compound structure, the Ki value becomes even smaller. Adenine is an example of a 
compound with groups residing in favorable contour regions. This compound has a Ki of 0.30 
µM. When a compound interacts with both positive and negative contour regions, the Ki 
increases; the Ki value for adenosine, for example, increases three-fold relative to adenine as a 
result of the bulky ribose group. The evolutional process taken when using these potentials to 
design compounds for synthesis is quite similar to the progression shown in Figure 5. It is 
important to make small changes and evaluate how the designed compound will fit within the 
steric and electrostatic potentials assigned by the model.  
Other important compounds to evaluate with this model are the pentamidine-, 
furamidine-, and melarsoprol-like compounds (Figure 6). Pentamidine, furamidine, and 
melarsoprol all have good affinity for the P2 transporter with respective Ki values of 0.37, 1.19 
and 0.54 µM. Contour regions of pentamidine, furamidine, and melarsoprol are displayed in 
Figure 6. These regions display several areas where some steric bulk and partial positive charge 
can be added to improve affinity for the P2 adenosine transporter. A loss of affinity will occur if 
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bulky substituents interact with the unfavorable yellow contour regions and/or if positive charge 
interacts with the red contour regions.  
With pentamidine, which is a very flexible compound, the final pharmacophore model 
yellow contours display most central atoms to be suitable for substituent addition; however, the 
area nearest the pharmacophore should not be modified. Melarsoprol is a more rigid structure, 
though rotation can occur throughout the compound. There can be rotation between the 
melamine ring and the phenyl and between the phenyl and the dithiarsolan ring. For this 
compound, the yellow contours reside near the melamine and the phenyl. This suggests that a 
loss of affinity may result from substituent addition to the atoms in these regions. Furamidine is a 
much more rigid and curved structure. For this structure, the yellow contours are much more 
abundant near the phenyls and yet away from the furan and the amidines. This is even clearer 
when the compound and its contour are viewed in three-dimensional space. The areas where 
yellow contours do not exist are optimum for substituent modification.  
The red contours encompass both pentamidine and furamidine, whereas blue contours 
surround melarsoprol. The blue contours appear to be based on the partial charge distribution. 
For the diamidine compounds the partial charge distribution is strongly localized at the amidines. 
This appears beneficial for binding to the transporter; however, it is evident that more charge to 
an amidine location will not improve binding. Instead a partial charge distribution that is shared 
within a ring structure appears to be more advantageous. This is seen in the melamine-like 
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structure of melarsoprol. Findings suggest that additional charge, which is less localized, may be 
able to improve binding of diamidine compounds.  
Discussion 
The efficacy of many drugs is determined to a large extent by the processes that govern 
their uptake into the cell or into the cellular compartment that is the site of action.
7, 17-19
 These 
processes obviously include transporters for water-soluble drugs but even rates of diffusion for 
lipophilic drugs. An example of the latter is chloroquin, which as a weak base diffuses across 
several membranes before it reaches the Plasmodium falciparum food vacuole where it is 
trapped by protonation and fatally inhibits heme polymerization.
20, 21
 Equally, efflux systems 
such as ATP-binding cassette transporters and the P. falciparum CRT1 channel-like protein have 
been implicated in resistance to drugs ranging from antibiotics and antiparasitics to 
antineoplastic drugs.
22, 23
 As such, detailed insights into the processes that determine drug flux 
across the (plasma) membranes of target cells are vital for the rational optimization of drug 
activity and both the prevention and bypassing of drug resistance.  
It is of pivotal importance that we gain insight into the molecular mechanisms by which 
transporters bind and thus select their substrates as this would allow us to construct models with 
predictive value, which would allow us to optimize substrate design. Although in silico screening 
of virtual libraries and predictions of substrate affinity are now possible for proteins with known 
or computable structure,
24-26
 this is not ordinarily possible for transporters as very few structures 
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have been obtained, and the protein structures, with usually 10–12 transmembrane domains, are 
highly complex and extremely difficult to crystallize, although there have recently been some 
notable successes, mostly with prokaryotic membrane proteins.
27-29
 One approach is to use the 
few known transporter structures as scaffolds for other transporters, by a computational process 
called fold recognition or threading. We recently obtained a model for the T. brucei brucei 
nucleobase transporter NBT1 by this process and validated it by site-directed and random 
mutagenesis.
30
 The creation of a structural model of the closely related Leishmania donovani 
LdNT1.1 nucleoside transporter by ab initio calculation was also very recently reported.
31
 
Although these approaches did produce approximate models for the overall structure of the 
transporters and identified key amino acid residues, they allow at best limited prediction of 
substrate selection, and only if the amino acids involved in binding have been separately 
identified. Thus, with the current technologies, it is exceedingly difficult to obtain the required 
functional insights with the protein structure as a starting point. 
A radically different approach was pioneered some time ago to study purine transport in 
T. brucei brucei by systematically altering the substrate and calculating inhibition constants, Ki, 
and from there binding energy G0.1, 18 This method was used to explain substrate preferences of 
purine and pyrimidine transporters in T. brucei brucei,
32
 Leishmania major,
33, 34
 Toxoplasma 
gondii,
35
 Leishmania mexicana,
36
 as well as the human NBT1 nucleobase transporter,
14
 human 
concentrative nucleoside transporters,
37
 and human equilibrative nucleoside transporters
38
 with 
semi-quantitative models of substrate binding that did not require any structural or genetic 
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information about the transport protein. However, this method still did not allow genuinely 
quantitative or three-dimensional predictions nor was it suitable for screening virtual libraries.  
In this study, we have adapted the method to address the above issues; energy-minimized 
three-dimensional structures of 112 compounds with experimentally obtained binding affinities 
for the TbAT1/P2 transporter were employed through the use of CoMFA and CoMSIA 
molecular descriptors for PLS model regression construction and analysis. The various 
molecules were preliminarily aligned by their common structural and chemical features, resulting 
in four datasets of compounds, Figure 2, A-D, large enough for individual model formation and 
analysis. This was followed by optimized alignment of all 112 compounds using four molecular 
descriptor contour potentials, negative and positive steric and electrostatic, as a guide. This has 
generated an in silico computational model into which new molecules can be entered to arrive at 
a reliable estimate of binding energy. This constitutes a first computational approach to the 
design of novel ligands for the TbAT1/P2 transporter and allows for in silico evaluation of large 
numbers of known and novel compounds as substrates. The computational analysis was 
validated to be statistically significant using leave-one-out cross-validation and 10-fold cross-
validation, as well as by other statistics and the internal predictability of this model, as displayed 
in Figure 4.  
The contour profiles of steric and electrostatic factors also allow fundamental insights 
into how various ligands interact with the transporter binding pocket. The P2 transporter, with its 
highly unusual substrate profile and involvement in drug transport and resistance,
2-5, 11, 39
 was 
 37 
 
chosen for this study to gain insight into how a transporter that is on the one hand completely 
selective for adenine and adenosine only (out of all nucleosides and nucleobases) can also bind 
molecules as diverse as isometamidium, melarsoprol, and furamidine with similar affinity. 
Previous studies already identified the “amidine” motif formed by R1−N1=C6(R2)−NH2 of 
adenine as the main motif responsible for P2 binding,
3, 11
 and it was further argued that the 
positive charge on N9 of adenine and adenosine, as well as the aromaticity of the purine, also 
makes important contributions to the high substrate affinity.
3, 18
  
The calculated substrate-transporter interaction contours for adenine and adenosine in 
Figure 5 now allow us to evaluate these earlier conclusions against the advanced modeling 
approach employed in this study. Figure 5 identifies four substrates that have a partial positive 
charge on the position of the amino group of 2-aminopyridine/adenine/adenosine as essential for 
optimal binding. Similarly, a partial negative charge is strongly favored at position 1, along with 
a positive charge at positions 8 and 9, whereas there is no clear electrostatic preference at 
positions 3 and 7 or most of the ribose moiety, except perhaps a preference for a positive charge 
at the 2’-position. Large substitutions are indicated as unfavorable in positions 1, 2, 8 and 2’, and 
at the 6-amino group of adenosine (Figure 5, yellow indicators), but the position of the ribose 
group does not appear to be restricted with respect to further expansion/elongation, in line with 
the positioning and high affinity of the long diamidines.  
The above interpretation of the CoMFA and CoMSIA models is entirely consistent with 
the experimentally obtained G0 values listed in Supplemental Table 1 (Appendix A). For 
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instance the importance of the partial negative charge on position 1, presumably as hydrogen 
bond acceptor, is demonstrated by the reduced affinity of 1-deazaadenosine versus adenosine 
((G0) = 9.7 kJ/mol) and of 1-deazapurine versus purine ((G0) = 4.9 kJ/mol). Similarly, the 
positive charge provided by the 6-position amine is quantified by comparison of purine riboside 
with adenosine ((G0) = 7.3 kJ/mol), purine with adenine ((G0) = 10.2 kJ/mol) and 6-
chloropurine riboside with adenosine ((G0) = 7.0 kJ/mol). As shown in Figure 7, this gives 
estimates of contributions of 9.7 and 8.2 kJ/mol for the N1 and 6-amino groups, respectively. 
The loss of both these groups should thus result in a loss of binding energy of approximately 16 
kJ/mol and this was demonstrated by comparing 2’-deoxyinosine with 2’-deoxyadenosine 
((G0) = 16.3 kJ/mol) and 1-deazapurine with adenine ((G0) = 15.1 kJ/mol). The strong 
contribution from N9 likewise follows from comparing 9-deazaadenosine with adenosine and 
4,6-diaminopyrimindine with 2-aminopyridine ((G0) = 6.4 and 5.7 kJ/mol, respectively). The 
relative unimportance of positions N3 and N7 was demonstrated using 3-deazaadenosine and 7-
deazaadenosine, respectively, as catalogued in Supplemental Table 2 (Appendix A), which also 
lists relative affinities for compounds with substitutions at positions 2 and 8.  
Finally, a substantial contribution to binding is made through interactions between the 
aromatic purine or benzamidine moieties and amino acids in the transporter binding pocket, 
through π-π stacking with aromatic residues, cation-π bonding or amino-aromatic interactions.40 
Although this cannot be directly demonstrated by the use of “nonaromatic purines”, which would 
have a completely different three-dimensional structure, uniquely for P2 this can be shown and 
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quantified by comparing aromatic and nonaromatic diamidines (Supplemental Table 2, Appendix 
A). The diagram in Figure 7 summarizes these data in the form of an interaction diagram 
between P2 transporter and adenosine. This figure, gained from experimental data and using a 
previously validated approach,
1, 18
 is in close agreement with data presented in Figure 5 based on 
the predictive PLS regression model. It is important however to be clear that both modeling 
approaches (Figures 5 and 7) are predictive with respect to substrate binding rather than 
translocation, i.e. it does not predict transport efficiency for any individual substrate. This 
limitation is not inherent to the computational approach, rather it is the result of using Ki values 
(transport inhibition through extracellular binding) instead of Michaelis-Menten constants (Km 
and Vmax values, determined from measurement of transport) as input for the models. A similar 
approach as followed here could predict transport, but it would have required radiolabeled 
analogues of all the compounds used in the study, and this was not feasible. We also would not 
wish to suggest that efficient uptake by a pathogen is sufficient to ensure efficacy of a potential 
therapeutic agent, as this requires optimal interaction with the intended intracellular target as 
well. In summary, we have developed and validated a novel computational approach to analyze, 
explain, and predict the interactions between transporters and their substrates that does not 
require prior knowledge of transporter structure or indeed primary sequence. 
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Tables and Figures 
Table 1. CoMFA and CoMSIA model statistics for the datasets A-D of Figure 2. 
     
CoMFA     
 A B C D 
Total  Compounds 36 29 16 16 
n 7 4 5 2 
q
2
cv 0.65 0.55 0.57 0.79 
SEE 0.29 0.32 0.17 0.12 
r
2
 0.93 0.89 0.98 0.99 
F 55.9 50.5 74.4 311 
     
CoMSIA     
 A B C D 
Total  Compounds 36 29 16 16 
n 5 3 3 2 
q
2
cv 0.50 0.55 0.65 0.61 
SEE 0.32 0.34 0.26 0.11 
r
2
 0.91 0.86 0.93 0.99 
F 62.5 51.5 47.4 358 
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Table 2. CoMFA and CoMSIA model statistics for the 112 compound database. 
 CoMFA CoMSIA 
Total  Compounds 112 112 
n 11 6 
q
2
cv 0.55 0.54 
q
2
10-Fold  0.56 0.54 
SEE 0.22 0.37 
r
2
 0.95 0.86 
F 190 109 
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Figure 1. Scaffolds for initial alignment: A, adenine; B, furamidine; C, stilbamidine; D, 
pentamidine; E, 1,1’-(nonane-1,9-diyl)diguanidine; F, melarsoprol; G, isometamidium. All 112 
compounds could be aligned to one of these scaffolds. Most compounds were in A-D. 
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Figure 2. First alignment processes produced seven different databases for the 112 compounds. 
The compounds of the larger datasets, A-D, were employed for QSAR CoMFA and CoMSIA 
studies. Resulting three-dimensional CoMFA molecular surfaces are shown for datasets A-D, 
which are labeled A-D, respectively. Steric contributions are shown in green (favors bulky 
substituents) and yellow (bulky substituents impact negatively on binding), and the electrostatic 
contributions are displayed in blue (favoring a positive charge) and red (favoring a negative 
charge).  
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Figure 3. Final alignment of 112 compounds, with adenine displayed in purple. 
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Figure 4. Actual versus predicted results from PLS models employing CoMFA (left) and 
CoMSIA (right) molecular descriptors. 
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Figure 5. Calculated three-dimensional molecular surfaces for analyses of compound structural 
relationships with P2 transporter inhibition. From left to right, the compounds shown above are 
2-aminopyridine, 4,6-diaminopyrimidine, adenine, and adenosine. Colors are as in Figure 2. 
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Figure 6. Three-dimensional molecular surfaces for pentamidine (top), furamidine (middle), and 
melarsoprol (bottom). Colors are as in Figure 2. 
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Figure 7. Model of adenosine, giving estimates of the contributions to the total binding energy of 
34 kJ/mol in the black numbers, with the red numbers indicating the position on the purine or 
ribose rings. The half-circles indicate positions where substitutions reduced the adenosine 
binding affinity. The aromatic rings are estimated to contribute approximately 12 kJ/mol to the 
binding energy, although this could not be verified directly, as a nonaromatic adenosine analog 
would have a completely different three-dimensional structure. However, comparisons between 
aromatic diamidines and nonaromatic diamidines (Supplemental Table 2, Appendix A) are 
consistent with this estimate. 
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A dataset of 55 compounds with inhibitory activity against L. donovani axenic 
amastigotes and L. amazonensis intracellular parasites was examined through three-dimensional 
quantitative structure-activity relationship modeling employing molecular descriptors from both 
rigid and flexible compounds. For training and testing purposes, the compounds were divided 
into two datasets of 45 and 10 compounds, respectively. Statistically significant models were 
constructed and validated via the internal and external predictions. For all models employing 
steric, electrostatic, hydrophobic, H-donor and H-acceptor molecular descriptors, the R
2
 values 
were greater than 0.90 and the SEE values were less than 0.22. The models obtained from rigid 
and flexible compounds were employed together to obtain a conservative method for predictions. 
This method minimized under predictions. Molecular descriptors from the models were then 
extrapolated, for the overall predictive devices and the individual compounds, and examined 
with regard to inhibitory activity. Information gained from the molecular descriptors is useful to 
the design of novel compounds. The models obtained can be employed to predict activities of the 
compounds designed and/or form predictions for compounds that exist and have not yet been 
examined with biological inhibitory assays. 
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Introduction 
Leishmania species cause leishmaniasis, which is an endemic disease found in tropic and 
subtropic regions riddled with poverty and neglect.
1-3
 This infection is most often in the form of 
cutaneous leishmaniasis, visible skin sores, or visceral leishaniasis, affected internal organs. 
Primarily transported through the bite of a female phlebotomine sandfly, millions of new cases 
are reported annually.
1, 4
 When untreated, tens of thousands of these parasitic infections result in 
death. 
Primary treatments for leishmaniasis include sodium stibogluconate and N-
methylglucamine, while secondary therapies, which are often toxic, include pentamidine 
isethionate, amphotericin B and paromomycin sulfate.
1, 5
 These classic treatments are costly and 
embedded with implications of high toxicity, resistance, pain, nausea, and diarrhea. Possible new 
therapies for the treatment of leishmaniasis have been examined and these include the 
implementation of liposomes, natural products, synthetic compounds and vaccines.
1, 6
 Most 
methods employing liposomes are costly and hence not feasible, while other methods of therapy 
improvement have showed promice.
1, 7
 Several natural products and synthetic compounds 
possess better therapeutic profiles with regard to activity and toxicity than the compounds 
currently used in treatment, while vaccine development has been too specific to Leishmania 
species and thus unsuccessful.
1
 
 60 
 
Through several research endeavors activities and toxicities of series of compounds have 
been gathered and such data have been implemented in rational drug design.
8-11
 These studies 
employ biological data of natural and/or synthetic compounds and computational tools to 
examine compounds with activity against Leishmania species. Examination of such compounds 
has led to the formation of predictive devices and from these devices the importance of some 
molecular structures has been ascertained. Although specific receptor interaction studies are 
important, especially when studying mechanisms, intact parasite studies of inhibition and 
toxicity are crucial for identifying compounds that will eradicate the parasite from hosts.
1
 Such 
studies of synthetic chalcones and phospholipids display effective antileishmanial activity for 
compounds with: (1) a long alkyl chain, (2) bulky group’s terminal the alkyl chain, and (3) an 
electron deficient group.
9, 12
  
Our studies examine a biological dataset of synthetic arylimidamides which possess 
activities against L. donovani axenic amastigotes and L. amazonensis intracellular parasites. 
Inhibitory data, in the form of IC50 values, and Comparative Molecular Field Analysis (CoMFA) 
and Comparative Molecular Similarity Indices Analysis (CoMSIA) molecular descriptors were 
employed for partial least squares (PLS) regression. Predictive models and resulting molecular 
descriptor potentials contribute to the identification and understanding of important molecular 
features that govern the inhibitory actives of arylimidamides against species of Leishmania. 
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Experimental Procedures 
Inhibitory Data. Briefly, IC50 (µM) values were gathered for compounds of interest using 
two assays. The first assay screened against axenic amastigote-like L. donovani, while the second 
screened against L. amazonensis intracellular parasites. Screening against L. donovani was 
conducted by:  (1) culturing Ld1s parasites in potassium-based medium at pH 5.5, 37 °C, (2) 
incubating for three days with compounds in a 96-well plate, and (3) adding tetrazolium dye and 
quantifying the assay spectrophotometrically. While screening against L. amazonensis 
intracellular parasites was conducted by: (1) plating macrophages and allowing adhering 
overnight, (2) adding  L. amazonensis promastigotes transfected with β-Lactamase gene (MOI: 
5:1) and incubating overnight, (3) adding compounds of interest and incubating for 72 hours at 
the temperature of interest, (4) adding nitrocefin in lysis buffer and incubating an additional 3 to 
5 hours, and (5) reading the plate at 490 nm.
13
 Experimental IC50 values for L. donovani axenic 
amastigotes and L. amazonensis intracellular parasites were obtained for 55 compounds.  
 Preparation of Compounds for Computational Studies. SYBYL 8.1
14
 software was 
employed to construct all compounds in three-dimensional space. Compounds were then divided 
into training and testing datasets. These datasets consisted of 45 and 10 compounds, respectively. 
The compounds of the training dataset then underwent a short molecular dynamics simulation of 
1 ns. This system employed SYBYL 8.1 default settings at a constant temperature and volume 
(NTV). Briefly, (1) the system temperature was 300K with a coupling constant of 100 fs, (2) 
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Maxwell-Boltzmann distribution was employed for initial atom velocities, (3) the non-bonded 
pair list was updated every 25 fs, (4) and the duration of the molecular dynamics simulations in 
vacuo was 1ns with a time step of 100 fs and a snapshot every 1000 fs.  This displayed several 
low energy structures. Torsional angles of all training dataset compounds were modified to 
explore the low energy conformations and modified compounds were minimized to convergence 
using the Tripos force field, conjugate gradient algorithm, and Gaseiger-Huckel charges. The 
termination gradient was 0.01 kcal/(mol Å) and the maximum iterations were 10
4
. 
Rigid Alignment of Compounds and Resulting Models. Each training dataset of 
compounds with modified torsional angles was aligned using the “Align Database” option of the 
QSAR module in SYBYL. Aligned structures were then analyzed through the use of molecular 
descriptors.  CoMFA (steric and electrostatic) and CoMSIA (steric, electrostatic, hydrophobic, 
H-donors and H-acceptors) molecular descriptors were calculated and PLS regression was 
employed to compare the molecular descriptors of compounds to obtained average IC50 values. 
The number of components was determined by the smallest predicted error sum of squares. 
Optimum models employing CoMFA molecular descriptors consisted of three components, 
whereas the ones with CoMSIA molecular descriptors employed six. 
Flexible Alignment of Compounds and Resulting Models. Five compounds with low IC50 
values for the L. amazonensis intracellular parasite assay were employed for flexible compound 
alignment using the “Align Pharmacophore” option of the GALAHAD module. Parameters were 
acquired through the “Suggest from Data” option and the best 20 models were gained. The 
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highest scoring model with respect to maximized pharmacophore consensus, maximized steric 
consensus, and minimized energy was employed as a template for individual compound 
alignment of the entire training dataset. The “Align Molecules to Template Individually” option 
was selected and parameters were acquired once more through the “Suggest from Data” option; 
the “Keep Best N Models” option was reset to 20. Molecular descriptors were calculated for the 
highest scoring model and PLS regression was implemented in the same manner as for the rigid 
compounds. The optimum numbers of components were determined as previously described; 
models with CoMFA molecular descriptors consisted of three components, whereas models with 
CoMSIA molecular descriptors employed six.  
Statistical Analyses. The statistics calculated from PLS regression included: a cross-
validated correlation coefficient (Q
2
), the coefficient of determination (R
2
), the standard error of 
estimate (SEE), the F statistic, a bootstrap R
2
 (R
2
bs), and a bootstrap SEE (SEEbs). The bootstrap 
analysis was used to check the stability of the models through cross-validation into two, five, and 
ten groups. The average values of the bootstrap analysis are displayed with the rest of the 
statistics.  
Testing Datasets and the Conservative Model Method. The models constructed from the 
rigid and flexible alignments were employed to examine testing datasets that were aligned via 
rigid and flexible methods. Of the pIC50 values predicted, for both training and testing datasets, 
the more negative pIC50 prediction was considered the most viable. This method favors over 
prediction rather than under prediction. 
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Molecular Descriptor Potentials. Molecular descriptor potentials acquired through the 
mapping of the product standard deviation with respect to molecular descriptor values and 
coefficients at each lattice point were extrapolated from the models. Default levels of contour by 
contribution were employed to gather favored and disfavored potentials for overall models. The 
individual compounds of the models were analyzed via the contour by actual analysis method. 
Software output was used to determine the proper ranges of assigned favored and disfavored 
contour regions for individual compounds.  
Results 
The entirety of the dataset, 45 training and 10 testing compounds, can be represented via 
the scaffold structure displayed in Figure 1. At each of the five positions labeled in this figure 
there are differing atoms or groups: positions one and four display single atom changes in the 
form of carbon, oxygen, sulfur, and nitrogen, whereas positions two, three and five display larger 
group substituent modifications.  
Biological IC50 values were acquired for each compound of the training and testing 
datasets through two assays targeting L. donovani axenic amastigotes and L. amazonensis 
intracellular parasites. These inhibitory values were averaged and standard deviations were 
acquired (Supplemental Table 3, Appendix B and Table 3). For modeling purposes, the IC50 
values were log transformed into pIC50 values (pIC50 = −log(IC50)). Figure 2 displays the pIC50 
data; experimental values against the L. donovani axenic amastigotes are shown in green, 
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whereas the values against the L. amazonensis intracellular parasites are displayed in blue. The 
standard deviations of the data are represented in general by trend lines and the averaged values 
are shown as triangles and squares, respectively. Notice that the slopes are very similar with 
values between 0.96 and 1.0, and R
2
 values are 0.95 or higher. This displays the relative range of 
inhibitory activity and respective deviations from the average inhibitory values associated with 
each synthetic compound in the training and testing datasets. The pIC50 distribution of data are 
also shown in this figure; the inhibitory activity of arylimidamides against L. donovani axenic 
amastigotes ranges between approximately -2.5 and 0.5, whereas those active against L. 
amazonensis intracellular parasites range between about -1.5 and 1.5.  
Compounds examined through biological assays were aligned in silico in three-
dimensional conformations using two methods: (1) rigid alignments of compounds were 
obtained through the implementation of the SYBYL “Align Database” option of the QSAR 
module, and (2) flexible alignments of compounds were acquired through the use of the 
“Pharmacophore Alignment” option of the GALAHAD module. Rigid alignments were 
preformed on low energy conformations of compounds. Molecular descriptors were then 
calculated and PLS regression was employed to construct predictive models implementing the 
descriptors and respective biological inhibitory data. The best computational models formed 
consisted of compounds in their most linear conformation with an overall plus one charge. 
Flexible alignment of compounds was also implemented. This process employed the five 
most active compounds against the L. amazonensis intracellular parasites from the training 
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dataset (Figure 3). Figure 4 displays the outcome of pharmacophore simulations that lead to PLS 
regression models employing flexible compounds. The rotation of the compounds allows for 
visualization of alignment and positioning of identified feature potentials. The observed features 
governing structure alignment are: (1) four aromatic rings (cyan); (2) N=C−N groups, two 
positive nitrogen (red) and a H-donor (magenta); (3) atoms at the one and a two position of 
Figure 1, two H-acceptor (green); (4) atoms at a five position, a H-donor or H-acceptor (overlaid 
magenta and green equates to dark green). Then, all of the training and testing compounds were 
flexibly aligned to the pharmacophore. These alignments can be viewed in relation to rigid 
alignments (Figure 5). Rigid compounds were aligned by N=C−N groups. Notice that there is a 
difference in the spatial relationships of the compounds. 
Inhibitory and compound structural data were employed to construct predictive models 
through PLS regression methods. The statistics for these models indicate that models employing 
CoMSIA molecular descriptors should outperform those constructed with CoMFA molecular 
descriptors (Table 1). This is shown in higher Q
2
, R
2
, and F statistics and lower SEE statistics for 
the models constructed with rigid compounds. Similarly, the models of flexible compounds 
displayed higher R
2
 and F statistics and lower SEE statistics. The low Q
2
 values for models of 
flexible compounds were attributed to: (1) torsional variability, (2) differences in optimal low 
energy structural conformations, and (3) contributions of compound inhibitory activities. Based 
on statistics, models with CoMSIA molecular descriptors were examined further with regard to 
molecular descriptors (Table 2). The factors governing these models were dominated by 
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hydrophobic potentials followed by H-donor potentials. Smaller contributions were made by H-
acceptor, steric, and electrostatic potentials, respectively.   
The internal (training dataset) and external (testing dataset) predictions of these models 
are displayed in Figure 6 through the plotting of predicted pIC50 values in relation to 
experimental pIC50 values. The training dataset of this figure is colored in accordance to Figure 
2, whereas all testing dataset predictions are in red. Although internal predictions were linear, 
some testing dataset compounds were more difficult to predict for than others. The variance in 
compound prediction differed between the models for compounds of rigid and flexible 
alignments; hence, by taking the most negative prediction of each compound regardless of rigid 
or flexible alignment and plotting these values against respective experimental data a 
conservative method for prediction can be obtained. The combination of the models reduces 
under prediction. Table 3 displays the testing dataset along with experimental average IC50 
values, plus or minus respective standard deviations, along with the conservative model IC50 
prediction; note that model error for each compound is not shown.  
From the models employing CoMSIA molecular descriptors, potentials were extrapolated 
and viewed in relation to the overall models (Figure 7) and individual compounds thereof (Figure 
8). Figure 7 displays the overall CoMSIA molecular descriptors for the rigid and flexible models. 
It is evident that each overall model displays different molecular descriptor potential 
contributions, for all molecular descriptors (steric, electrostatic, hydrophobic, H-donor and H-
acceptor). This indicates that each model is constructed somewhat differently; although, there are 
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similarities between the potentials obtained. Using the positions of Figure 1 as a reference: (1) 
steric bulk is favored (green) at positions three and five and perhaps not symmetrically, whereas 
disfavored steric bulk (yellow) regions are just outside those favored, (2) positive electrostatic 
charge is favored (blue) at one, if not both, of the N=C−N groups near position five, whereas 
negative charge is favored (red) predominantly at or near position one and outside one of the 
N=C−N groups, (3) hydrophobic interactions are favored (yellow) at positions two and five, 
whereas disfavored hydrophobic interactions (gray) are near three positions and outside five 
positions, (4) H-donor atoms are favored (cyan) predominantly at or below the five position and 
disfavored (purple) in regions beyond favored regions and on three positions, and (5) H-
acceptors are favored (magenta) near the terminal N=C−N groups, and disfavored (red) below 
the four position(s) and outside favored N=C−N groups of the comparison molecule DB766. 
With regard to the scaffold structure of Figure 1, Figure 8 displays the molecular 
descriptor potentials of individual compounds extrapolated from respective models employing 
CoMSIA molecular descriptors. The molecular descriptor potential regions of individual 
molecules appear to be more consistent within their respective rigid and flexible models than 
they were in the overall models of Figure 7. However, the molecular potentials that resulted were 
also fewer. These included favored and disfavored hydrophobic, favored H-donor and favored H-
acceptor potentials. With X of Figure 8 representing positions one through five of the Figure 1 
scaffold structure and biological inhibitory data in Supplemental Table 3 (Appendix B), it is 
possible to examine not only the molecular descriptor potentials with regard to model 
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contribution but also the contribution of substructures to biological inhibitory activity. To most 
effectively describe these findings, it is important that comparisons are made to a compound that 
is active in both datasets. DB766 was selected for analyses.  
With respect to Figure 1, the molecular descriptor potentials for DB766 include: (1) 
favored hydrophobic potentials near the aromatic rings consisting of the four position, opposite 
position three, and on the flanking five position aromatic rings, (2) favored H-donor potentials 
are displayed below the left five position N=C−N group, and (3) favored H-acceptor potentials 
are on the N=C−N group opposite the side of the favored H-donor and extended to the outer 
aromatic ring. The IC50 values for this compound against L. amazonensis intracellular parasites 
and L. donovani axenic amastigotes are 0.09 and 0.50 µM, respectively. The general structure of 
DB1867, compared to DB766, differs only by a sulfur atom at position one and with this change 
the compound becomes more linear and favored hydrophobic interactions are spread to positions 
one and two. Potentials for favored H-acceptors are near N=C−N groups and the IC50 values are 
0.05 and 0.68 µM, respectively. DB946 is the only compound in the training dataset to differ 
from DB766 at position two; this compound also differs at position three. The methyl groups at 
position two fill similar special areas as substituents in position three. Favored hydrophobic 
potentials reside in position two, three, and five locations. This compound’s IC50 values are 0.11 
and 0.37 µM, respectively. DB667 and DB1876 differ from DB766 at position three. DB667 
consists of hydrogen atoms at position three and molecular descriptor potentials similar to those 
of DB946 (hydrophobic) and DB766 (H-donor and H-acceptor); although, the favored 
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hydrophobic potentials span a greater length for DB667. The IC50 values for this compound are 
0.53 and 1.6 µM, respectively. DB1876 displays large disfavored hydrophobic molecular 
descriptor potentials at the three positions. The remaining potentials are favored hydrophobic 
potentials near the aromatic rings and favored H-donor and H-acceptor potentials near the 
N=C−N group(s). This compound has IC50 values of 2.1 and 28 µM, respectively. DB1851 
differed from DB766 at position four. This resulted in favored hydrophobic interactions that span 
more of the molecule than previous compounds discussed and H-donor and H-acceptor potentials 
similar to those of DB1876. The IC50 values for these compounds are poor, greater than 10 and 
50 µM, respectively. DB1921, DB1942, and DB1906 all differ from DB766 at the five positions. 
DB1921 is flanked at the five positions and has different substituents at the three positions. This 
compound consists of potentials similar to DB1876; however, it is also missing most of the 
favored hydrophobic and H-acceptor potentials. The IC50 values for this compound are 4.7 and 
41 µM, respectively. DB1942 consists of a longer more flexible ring structure than DB766 and 
consists of disfavored hydrophobic molecular descriptor potentials primarily at the five positions. 
Positive hydrophobic potentials are on the inner aromatic rings or the outer rings near the five 
position, whereas H-donors are favored on one side of a N=C−N group and H-acceptors are 
favored at both N=C−N group(s). This compound has IC50 values of 0.81 and 3.6 µM, 
respectively. The five positions of DB1906 consist of more rings than DB766. The molecular 
descriptor potentials for this compound were similar to those of DB766 (hydrophobic and H-
donor) and DB946 (H-acceptor), IC50 values are 0.27 and 1.9 µM, respectively.  
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Discussion 
Studies examined chalcones and phospholipids and found that high inhibitory activity 
occurred when compounds possessed a long alkyl chain, bulky groups terminal the alkyl chain, 
and an electron deficient group.
9, 12
 The structures of chalcones and phospholipids are quite 
different from each other, and these compounds differ substantially from the arylimidamides 
examined in this study (Figure 1 and Supplemental Table 3, Appendix B).   
The numbered locations of Figure 1 aid in the explanation of inhibitory data displayed in 
Figure 2 through the interpretation of pharmacophore consensus potentials (Figure 4) and 
molecular descriptor contribution potentials (Figures 7 and 8). The pharmacophore alignment of 
Figure 4 is calculated using the compounds of Figure 3. By only employing the most active 
compounds, the pharmacophore is strictly for compounds of similar structure and inhibitory 
activity. The pharmacophore results suggest importance of aromatic and positively charged 
N=C−N groups. These can be related to the bulky groups flanking the alkyl chain and the 
electron deficient group, respectively. The long alkyl chain may be related to the long carbon 
backbone that is in part aromatic groups and/or the carbons of the furan that link the rings. 
PLS regression of calculated molecular descriptor potentials and respective biological 
inhibitory values, for both the rigid and flexible alignments of compounds presented in Figure 5, 
produced statistically significant models; yet, those employing the CoMSIA molecular 
descriptors from rigid structure alignment were the only ones with Q
2
 values greater than 0.5 
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(Table 1). It has been stated for years that if Q
2
 values are greater than 0.5 then the model has 
predictability better than chance.
14
 What we realize from our models, especially those aligned by 
flexible conformations, is that each compound contributes to the entirety of the model and that 
the models constructed from molecular descriptors of flexible compounds may be predicting just 
as well, if not better, than those constructed from molecular descriptors of rigid compounds 
(Figure 6). The rigid models of Figure 6 produce a greater amount of under prediction than the 
flexible models. For example, for the rigid model, one of the compounds active against L. 
donovani has an experimentally determined pIC50 value of -1.7 and a predicted value of 0, these 
IC50 values are 50 and 1, respectively, whereas for the flexible model the same compound has a 
predicted pIC50 value of -1.7, the same as the experimental value.  
Under prediction is a problem that needs to be addressed since predictive models such as 
the ones constructed in this study can be employed to scan potential candidates for synthetic drug 
design. Often synthetic measures are costly and timely; hence, it is better to synthesize only 
compounds expected to have the best inhibitory activity and disregard those expected to have the 
worse. To minimize under prediction, the minimum pIC50 predictions from the rigid or flexible 
models were plotted against the average experimental values. These data are shown as the 
conservative predictions of Figure 6. In this column we see that under predictions are no longer 
occurring for these models; yet, there are still over predictions. Over predictions, as long as they 
are few, are not as problematic since these values are larger and synthetic measures will most 
likely result in biologically obtained inhibitory activity better than calculated. 
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From models, such as the ones constructed during this study, molecular descriptor 
contributions can be obtained and observed. A previous study that employed CoMSIA molecular 
descriptors found that steric and hydrophobic interactions governed the model.
9
 This study was 
for synthetic phospholipids. Similarly, our model was governed by hydrophobic interactions; yet, 
this contribution of molecular descriptor interactions was followed by H-donor, H-acceptor, 
steric and then electrostatic (Table 2). When the overall CoMSIA potentials for each molecular 
descriptor are visualized, compound structures appear applicable for modifications. Figure 7 
allows for comparison between the models and overall analyses. It is important to realize that 
molecular descriptor potentials are unique to each model; hence, no two models are the same. As 
was found important previously, positive blue electrostatic potentials display the importance of 
the N=C−N groups, whereas the steric and hydrophobic potentials show the importance of the 
rings and substituents. To fully understand molecular descriptor contribution in relation to 
biological inhibitory data, it is important to analyze the potentials of individual compounds; a 
select set of which are shown in Figure 8. These potentials display much more consistency than 
those for the overall models of Figure 7.  
New compounds can be designed by employing the data acquired from the 
pharmacophore (Figure 4) and extrapolated molecular descriptor potentials (Figures 7 and 8). To 
do this, the basic pharmacophore must remain intact and the potentials of the overall models and 
those of individual compounds should be used for guidance. Since the importance of 
hydrophobic, H-donor and H-acceptor atoms are clearly displayed as essential potentials for the 
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individual compounds in Figure 8; this is a good place to begin. The favored hydrophobic 
potentials of the four aromatic rings exhibit significance (Figures 7 and 8); these are also seen as 
important in the pharmacophore (Figure 4). Hence, it appears imperative that the four rings 
remain a constant in our initial modeling efforts. H-donors appear to be important to regions near 
the N=C−N groups (Figures 7 and 8). One of the N=C−N groups is shown as essential in the 
pharmacophore (Figure 4). Likewise, H-acceptors appear to be significant to the region including 
and between the N=C−N groups and the N of the outer most aromatic rings (Figures 7 and 8). 
One such region was identified in the pharmacophore (Figure 4). Based on these observations, 
new compounds have been designed and predictions have been obtained (Figure 9). The ranges 
include the smallest and largest prediction obtained via the models constructed of rigid and 
flexible compound structures. 
In summary, by employing such findings it is possible to scan for potentially active 
compounds both efficiently and conservatively through the use of predictive models. The 
governing of inhibition results as models are employed and new compounds are designed, 
activities are predicted, compounds are synthesized, and biological assays provide experimental 
data for analyses. 
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Tables and Figures 
Table 1. Statistics of partial least squares predictive models for a biological dataset of synthetic 
arylimidamides with activities against L. donovani axenic amastigotes (LD) and L. amazonensis 
intracellular parasites (LA).  
  Rigid Alignment Flexible Alignment 
  CoMFA CoMSIA CoMFA CoMSIA 
  LA LD LA LD LA LD LA LD 
Q
2 
 0.23 0.25 0.47 0.59 0.16 0.60 0.07 0.22 
SEE  0.45 0.41 0.25 0.18 0.24 0.33 0.16 0.14 
R
2 
 0.68 0.77 0.91 0.96 0.91 0.85 0.96 0.97 
F  29.1 44.5 61.4 137 131 78.0 159 229 
SEEbs  0.35 0.37 0.21 0.16 0.21 0.26 0.12 0.12 
R
2
bs  0.80 0.82 0.94 0.97 0.93 0.90 0.98 0.98 
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Table 2. Contribution of CoMSIA molecular descriptors for rigid and flexible models employing 
structures of training dataset compounds and respective biological activities.  
   Rigid Alignment Flexible Alignment 
  L. amazonensis L. donovani L. amazonensis L. donovani 
Steric 0.15 0.14 0.13 0.13 
Electrostatic 0.11 0.08 0.14 0.15 
Hydrophobic 0.47 0.43 0.33 0.34 
H-Donor 0.15 0.21 0.20 0.21 
H-Acceptor 0.12 0.14 0.20 0.17 
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Table 3. Predictions in terms of IC50. Experimental values for compound inhibitory activity 
against L. donovani axenic amastigotes (LD) and L. amazonensis intracellular parasites (LA) are 
displayed in columns LD Calc and LA Calc. The predicted values are those from the 
conservative predictions of Figure 6.  
Name Structure LA Exp LA Calc LD Exp LD Calc 
DB710 
 
0.16 ± 0.04 1.4 0.84 ± 0.2 4.0 
DB712 
 
0.56 ± 0.08 0.65 2.0 ± 0.6 4.6 
DB749 
 
3.1 ± 0.7 1.4 >50 50 
DB874 
 
1.4 ± 0.3 0.66 4.2 ± 1.3 3.2 
DB889 
 
0.11 ± 0.02 2.3 1.7 ± 0.5 10 
DB1856 
 
0.74 ± 0.3 3.2 5.8 ± 0.7 10 
DB1857 
 
0.37 ± 0.2 0.69 1.0 ± 0.2 10 
DB1864 
 
>10 9.3 5.6 ± 1.8 16 
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Table 3 (continued) 
Name Structure LA Exp LA Calc LD Exp LD Calc 
DB1908 
 
>10 4.7 14 ± 1 16 
DB1930 
 
5.5 ± 0.2 9.3 >100 63 
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Figure 1. Scaffold structure for compounds being employed to examine biological inhibitory data 
through quantitative structure-activity relationships of L. donovani axenic amastigotes and L. 
amazonensis intracellular parasites. All training dataset structures and respective inhibitory data 
can be viewed in Supplemental Table 3 (Appendix B). 
Scaffold Structure 1. Backbone of   
47 training and all 10 testing 
compound .
Scaffold Structure 3. Backbone 
of DB1911 and DB1945.
Scaffold Structure 3. Backbone of 
DB1881, DB1882, and 1910. 
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Figure 2. Biological pIC50 data of synthetic arylimidamides active against L. donovani axenic 
amastigotes (green) and L. amazonensis intracellular parasites (blue). The negative log values of 
average experimentally obtained IC50 data, displayed in Supplemental Table 3 (Appendix B) and 
Table 3, and these values plus and minus respective standard deviations are all plotted against the 
negative log value of average experimentally obtained IC50 data. 
Experimental pIC50 Values
y = 0.96x - 0.11
R² = 0.98
y = 0.97x + 0.13
R² = 0.95
y = 0.98x - 0.08
R² = 0.99
y = 1.0x + 0.11
R² = 0.99
-2.5
-1.5
-0.5
0.5
1.5
-2.5 -1.5 -0.5 0.5 1.5
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Figure 3. Five of the most active compounds against L. amazonensis intracellular parasites and L. 
donovani axenic amastigotes.   
DB745
DB946
DB766
DB1862
DB1867
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Figure 4. GALAHAD potentials as identified by simulations employing the compounds of 
Figure 3. The identified features are color coded: cyan, hydrophobes; magenta, donor atoms; 
green, acceptor atoms; red, positive nitrogens. 
Initial 
View
+90 
+180 
+270 
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Figure 5. Final training (top) and testing (bottom) datasets: flexible alignments (left) and rigid 
alignments (right).  
Flexible Alignment Rigid Alignment
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Figure 6. Internal (blue and green) and external (red) predictions. The internal predictions are 
those for the training dataset compounds implementing the model constructed, whereas external 
predictions are those for the testing dataset compounds. The models have never seen the testing 
datasets. The L. amazonensis experimental versus predicted results are shown in blue above 
those for L. donovani in green. The experimental versus predicted results from left to right are 
predictions from implementing rigid (left) and flexible (center) compounds. The conservative 
predictions (right) are essentially the more negative of the two pIC50 predictions resulting from 
the models with rigid and flexible compounds. Since the scale observed is the negative log of the 
IC50, this method reduces under prediction. 
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Figure 7. Overall models with CoMSIA molecular descriptors for both rigid and flexible 
compound alignments. DB766 is displayed as a reference compound for each molecular 
descriptor potential. Favored potentials from steric to H-acceptor molecular descriptors are 
green, blue, yellow, cyan, and magenta, whereas disfavored potentials from steric to H-acceptor 
molecular descriptors are yellow, red, gray, purple, and red. 
 89 
 
 
Figure 8. CoMSIA findings with respect to Figure 1 and molecular descriptor potentials of 
Figure 7. The favored hydrophobic potentials have been changed to orange to improve 
visualization and insure that steric potentials were not displayed. The left most column consists 
of numbers correlated to positions of Figure 1. The column to the right consists of the 
compounds name. This is followed by the compounds and their respective molecular descriptor 
potentials for each the final models.  
X Compound 
L. amazonensis L. donovani 
Rigid Flexible Rigid Flexible 
0 DB766 
   
 
1 DB1867 
  
  
2 DB946 
    
3a DB667 
    
3b DB1876 
 
  
 
4 DB1851 
    
5a DB1921 
    
5b DB1942 
 
 
  
5c DB1906 
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Figure 9. Compounds designed using the pharmacophore data of Figure 4 and the CoMSIA 
molecular descriptor fields of Figures 7 and 8. The structures of the compounds are to the left of 
the predicted IC50 ranges. Ranges of predicted IC50 values were acquired through the use of both 
models constructed of rigid and flexible compounds.  
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Trypanosoma cruzi, which affects millions of people in endemic areas of Latin America, 
is the etiological agent of Chagas disease. The available therapy is not ideal since it presents 
limited efficacy, especially in chronic patients, and displays considerable side effects; thus the 
need for new trypanocidal compounds is indisputable. In vitro assays have been used to 
determine the biological activities of diamidines and arylimidamides against T. cruzi at two 
tempertures relating to that of blood stored at blood banks (4°C) and that of the human body 
(37°C). Our studies employ the corresponding biological IC50 values acquired to examine 
compound structural importance through computational biology. Hence, a pharmacophore was 
identified and implemented to assess quantitative structure-activity relationships (QSAR) 
through partial least squares (PLS) regression modeling employing the biologically obtained IC50 
values and computationally calculated comparative molecular field analysis (CoMFA) and 
comparative molecular similarity indices analysis (CoMSIA) molecular descriptors. Statistically 
significant models were acquired; these models have Q
2
 values greater than 0.51 and R
2
 values 
greater than 0.94.
 
Models were internally and externally validated and the molecular descriptor 
potentials were extrapolated for overall models. The computational data acquired can be used to 
screen for compounds with inhibitory activities against T. cruzi and design novel therapeutic 
agents.   
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Introduction 
Trypanosoma cruzi is the protozoan parasite that causes Chagas disease (CD), a tropical 
illness that affects 12-14 million people in many developing countries of Latin America and puts 
about 50 million at risk of infection.
1
 The occurrence of CD in nonendemic regions such as the 
United States and Europe is mainly due to the migration of infected people but also represents an 
important concern in these areas.
2-4
 
CD has two successive phases: a short acute phase characterized by patent parasitemia 
followed by a long, progressive chronic phase. The acute phase starts shortly after the infection 
and is often nonsymptomatic but may manifest as flu-like symptoms with a self-limited febrile 
illness that lasts a few weeks. If untreated, the symptomatic chronic disease develops in about 
20-40% of the infected individuals after a long latent period (several months and even decades), 
while the majority of the patients remain in the indeterminate state.
5, 6
 Due to the long, 
asymptomatic state, CD is considered a “silent killer,” impairing early specific diagnosis and 
treatment.
7
 The main clinical chronic manifestations of CD include cardiac and/or digestive 
alterations.
8
 CD is responsible for considerable rates of mortality and morbidity, however, in the 
centennial of its discovery by Carlos Chagas (1909), no prophylactic or efficacious treatment is 
available.
9
 
Although they provide limited efficacy and activity upon different parasite stocks, 
especially for the chronic sufferers, and cause deleterious side effects, the currently accepted 
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clinical treatments for Chagas are Nifurtimox (Nfx) and Benznidazole (Bz); these two nitrogen-
based compounds were introduced more than four decades ago.
10, 11
 Thus, the limitation of the 
current treatment for CD justifies the search and screening of other drugs that could replace Nfx 
and Bz and/or could be used in cases of therapeutic failure.
12
 
Aromatic synthetic diamidine (DA) and arylimidamide (AIA) compounds have been 
identified as potential therapeutics for CD.
9, 12-22
 Our biological assays for DA and AIA 
compounds have resulted in inhibitory activity assessment for 47 compounds at temperatures of 
4°C, the temperature of blood stored in blood banks, and 37°C, the temperature of the human 
body. In this study, the data from our biological assays were employed to develop predictive 
models and examine the structural importance of these compounds at the two temperatures. A 
pharmacophore for active compounds was acquired and implemented in quantitative structure-
activity relationship (QSAR) examination through partial least squares (PLS) regression 
modeling employing biologically obtained inhibitory values, in the form of IC50 data, and 
computationally calculated comparative molecular field analysis (CoMFA) and comparative 
molecular similarity indices analysis (CoMSIA) molecular descriptors. Subsequent to acquiring 
statistically significant and validated predictive models, molecular descriptor potentials were 
extrapolated from final models and employed along with the pharmacophore and predictive 
models to gain insight into compound structural importance for the inhibition of T. cruzi.  
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Experimental Procedures 
Compounds. DA and AIA compounds were synthesized, and stock solutions were 
prepared in dimethyl sulfoxide (DMSO) with the final concentration not exceeding 0.6%, which 
did not exert any toxicity towards the parasite or mammalian host cells (data not shown). 
Parasites. At peak parasitaemia, bloodstream trypomastigotes (BT; Y strain) were 
harvested by heart puncture from T. cruzi infected Swiss mice as previously reported. All 
procedures were carried out in accordance with the guidelines established by the FIOCRUZ 
Committee of Ethics for the Use of Animals (approved protocol number: CEUA L-028/09). 
Trypanocidal Analysis. IC50 values of 47 compounds were previously published.
13-16, 18-21
 
These data were acquired through bloodstream trypomastigotes (BT) assays. Treatment entailed 
different protocols as follows: BT (5 X 10
6
 per mL) were incubated for 24 h at 37ºC in RPMI 
1640 medium (Roswell Park Memorial Institute, Sigma Aldrich, USA) supplemented with 5% 
FBS, in the presence or absence of serial dilutions of each compound (0 to 32 µM). Alternately, 
experiments were performed at 4ºC with BT maintained in freshly isolated mouse blood (96%) 
in the presence or absence of serial dilutions of the compound (0 to 200 μM). After drug 
incubation, the parasite death rates were determined by light microscopy through the direct 
quantification of the number of live parasites using a Neubauer chamber, and the IC50 values 
were then calculated. The IC50 values were averaged for at least three determinations done in 
duplicate.  
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Computational Biology. All 47 compounds (41 training compounds and 6 testing 
compounds) with IC50 values were constructed in SYBYL 8.1
23
 on a Fedora Core 5 Linux 
workstation. Structures for each compound were energy minimized to convergence using the 
conjugate gradient method, Tripos force field, and Gasteiger-Hückel charges. The termination 
gradient was 0.01 kcal/(mol Å) and the maximum iterations were 10
4
. Compounds were then 
semi-randomly separated into training and testing datasets of 41 and 6 compounds, respectively. 
Compounds selected for the testing dataset represented the entirety of the dataset; they had 
diverse backbones and biological activities.  
The GALAHAD module in SYBYL was employed to gain a pharmacophore for 
inhibitory compounds of the training dataset; four compounds (DB1831, DB1853, DB1868 and 
DB766) with low IC50 values (Supplemental Table 4, Appendix C) were employed and the 
parameters were acquired through the “Suggest from Data” option. The best model resulted in 
maximized pharmacophore consensus, maximized steric consensus, and minimized energy. Due 
to the structural diversity of compounds in the training and testing datasets, compounds were 
aligned by the atoms of key features using the “Align Database” option of the QSAR module in 
SYBYL. Identified important structural atoms were used as a template; DB766 was employed 
for Cartesian coordinates. Compounds without the common structure were aligned by central 
atoms that were similar. 
PLS analyses employed the training datasets. Computationally calculated CoMFA and 
CoMSIA molecular descriptors were calculated and mathematically modeled with respect to log 
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transformed biologically acquired IC50 values; pIC50 = −log(IC50). Predictive models were 
gained and implemented to predict pIC50 values for compounds of the training and testing 
datasets. These models were then used to examine molecular descriptor contributions through 
model extrapolated molecular potentials; visualization was attained by contribution through the 
mapping of the product standard deviation with respect to molecular descriptor values and 
coefficients (S.D.*Coeff.) at each lattice point. The default levels of the contour by contribution 
were employed as follows: 80% for a favored region and 20% for a disfavored region.  
Results 
Inhibitory experimental assays against T. cruzi at 4°C and 37°C provided IC50 values for 
47 compounds (Supplemental Table 4, Appendix C). All compounds with inhibitory data were 
constructed in SYBYL and four compounds with low IC50 values, for both assays, were 
employed for pharmacophore identification. It is important to note that the best inhibitory 
compounds of this dataset are all AIAs. Given the structural variation of this dataset, only a 
select set of features are applicable for the alignment of all compounds.   
Figure 1 displays the pharmacophore potentials; structural importance appears to be 
attributed to the central furan and its flanking aromatic rings. These rings are identified by 
hydrophobe potentials. Using DB766 as a reference compound (Figure 2), Figure 1 also displays: 
(1) a fourth hydrophobe potential residing on one of the isopropyl substituents, (2) donor 
potentials at the N=C−N groups, (3) an acceptor potential on the furan O, as well as on both 
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isopropyl O, and (4) a positive N potential at one N=C−N group. Perhaps the importance of the 
one identified positive N comes from the net compound +1 charge of most AIAs. The 
pharmacophore identification appeared to highlight the rigid central structure of the compounds; 
the central structure is similar for AIAs and DAs. 
Atoms representing the hydrophobe and acceptor potentials were identified and 
implemented for training and testing dataset alignment; the atoms used in alignment are those 
identified in Figure 2. An effective overlay of the 41 training and 6 testing compounds allowed 
for three-dimensional compound comparison. The identified pharmacophore regions that were 
not used for alignment were still maintained by AIAs (Figure 3). With compounds aligned, 
CoMFA and CoMSIA molecular descriptors were calculated and these were employed along 
with the experimentally obtained inhibitory values for QSAR studies with PLS modeling. The 
models constructed have correlation coefficients (Q
2
)
 
values greater than 0.51, standard error of 
estimate (SEE) values lower than 0.29, coefficient of determination (R
2
) values greater than 0.94, 
and large F statistics (Table 1).  
Both CoMFA models consisted of approximately 70% steric and 30% electrostatic 
molecular descriptor contributions, while the CoMSIA models exhibited more variation. The 
model employing experimental inhibitory data at 4°C consisted of roughly 13% steric, 13% 
electrostatic, 23% hydrophobic, 26% H-donor, and 25% H-acceptor contributions, whereas the 
model with experimental inhibitory data at 37°C consisted of roughly 14% steric, 13% 
electrostatic, 26% hydrophobic, 24% H-donor, and 23% H-acceptor contributions. The molecular 
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descriptor contributions for both CoMSIA models were within 3% of each other; this difference 
is not statistically significant. However, molecular descriptor contributions are related to the 
weights that are employed by PLS to relate structural importance to inhibitory activity. This 
relationship results in predictions. These molecular descriptor contributions suggest that 
predictions from models employing CoMFA molecular descriptors will be more similar than 
those from models employing CoMSIA molecular descriptors. 
Figure 4 displays the training and testing dataset predictions for the PLS models; 
trendlines are displayed for the training dataset predictions. Training data are displayed in blue 
and green for the assays at 4°C and 37°C, respectively. Notice that the slopes of the trendlines 
are all near one as expected for a valid model. Also, there are very few noticeable outliers. 
Hence, the models should all be able to provide useful predictions for the compounds of the 
testing dataset. This holds true according to the testing dataset predictions, the CoMFA model at 
4°C and the CoMSIA model at 37°C are outperforming the other two models. The compounds of 
the testing dataset can be viewed along with their experimental and predicted data in Table 2. 
Notice that each of the testing compounds is quite different; they vary in size, shape, and 
conformation. This allows for a full predictability range inspection based on compound structure.  
The phenyl-pyridine DA DB1627 consists of accurate predictions, especially since the 
inhibitory values for this compound are at an experimental cut-off. 10SAB031 is a DA that 
consists of a triazole center ring and flanking aromatic rings, the amidines are in the m-position. 
The models constructed of CoMFA molecular descriptors predicted better than those with 
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CoMSIA molecular descriptors. DB1362  consists of a 3-bromo-4-methylthiophene central ring 
and flanking aromatic rings. The amidines for this DA compound are in the p-position. The 
model constructed of experimental data at 4°C and CoMFA molecular descriptors predicted best, 
as did the model with experimental data at 37°C and CoMSIA molecular descriptors. 14SMB013 
is a diamidine compound that has an aliphatic linker instead of a central ring. Again, the model 
constructed of experimental data at 4°C and CoMFA molecular descriptors predicted best, as did 
the model with experimental data at 37°C and CoMSIA molecular descriptors. AIA 613A, has a 
scaffold structure similar to DB766; yet, this compound lacks isopropyl substituents and N in the 
outer aromatic rings. As before, the model constructed of experimental data at 4°C and CoMFA 
molecular descriptors predicted best, as did the model with experimental data at 37°C and 
CoMSIA molecular descriptors. DB1868 is the most active compound of the testing dataset. This 
compound is similar in structure to DB766; it has additional O-Me at the p-positions of the outer 
aromatic rings. Both models constructed from experimental inhibitory data at 4°C predict well, 
while those for data at 37°C are over predicting significantly. It is also important to note that the 
largest deviations in predictions occurred when the experimental values between the two assays 
were the greatest. These deviations are seen in the predictions for 10SAB031, 14SMB013, and 
DB1868. The residuals between the two biological assays are 0.32, 0.53, and 0.65, respectively. 
Molecular descriptor potentials were extrapolated from all four models (Figures 5 and 6). 
Figure 5 displays the steric and electrostatic potentials for the models constructed with CoMFA 
molecular descriptors and inhibitory data at 4°C and 37°C, respectively. The model with CoMFA 
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molecular descriptors and inhibitory data at 4°C show that steric bulk is favored (green) on both 
ends of reference compound DB766, as well as above the furan and an isopropyl group. Yet, 
disfavored steric potentials (yellow) suggest a size limit to regions near isopropyl substituents. 
The electrostatic potentials display the N=C−N groups to exhibit favored (blue) positive charge. 
There are very few areas which call for negative charge (red). The model with CoMFA 
molecular descriptors and inhibitory data at 37°C display steric potentials similar to those of the 
model constructed from the data collected at 4°C. The electrostatic potentials again show 
importance of an N=C−N group and suggests more regions where negative charge is favored.  
Figure 6 displays the molecular descriptor potentials for the models employing CoMSIA 
molecular descriptors. These models displayed smaller more defined regions of importance than 
those previously discussed. The model constructed of CoMSIA molecular descriptors and 
inhibitory data at 4°C, show similar steric findings to those from the CoMFA models. Steric bulk 
is favored at both ends of the compound and there is a size limit to regions of isopropyl 
substituents. Electrostatic potentials identify important positive charge regions as those 
consisting of isopropyl substituents. Hydrophobic regions are favored (yellow) near the outer 
aromatic rings and disfavored (white) by the central furan ring. H-donors are favored (cyan) near 
the N=C−N groups, as are H-acceptors (magenta). The model constructed of CoMSIA molecular 
descriptors and inhibitory data at 37°C displays similar results to the model with CoMSIA 
molecular descriptors and inhibitory data at 4°C. Slight differences in steric potentials were seen 
in a shift of positive steric bulk potential from one isopropyl substituent region to the other 
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isopropyl substituent. Favored positive electrostatic potentials were reduced and favored 
negative electrostatic potentials were increased. A greater amount of favored hydrophobic 
potential resulted along the backbone of the reference structure, whereas the amount of 
disfavored hydrophobic potential expanded into regions that were previously favored. Favored 
H-donor potentials shifted toward the outer aromatic rings, while disfavored potentials were 
increased near one of these rings. The favored potentials for H-acceptors surround the N=C−N 
groups, whereas disfavored H-acceptor areas are located below the interior aromatic and furan 
rings, as well as near one of the isopropyl substituents. 
Discussion 
Found historically in rural areas of Latin America among those living in close proximity 
with vectors and in poor housing conditions, Chagas disease is spread through vectors, 
transfusion, organ transplant, and from mother to infant.
4, 12
 This disease has spread with 
migration to the United States and Europe. An estimated 100,000 people in the United States 
have this disease which is often unrecognized until the chronic phase is reached. The only 
accepted clinical treatments are Nfx and Bz, both of which are not approved for treatment in the 
United States. The only way to obtain these compounds is from the CDC, due to their adverse 
side effects that can be as devastating as the disease. Hence, the spread of Chagas disease and the 
limitations of current therapies necessitate the screening and development of therapeutics that 
could replace Nfx and Bz or be used in cases of therapeutic failure. Since several studies have 
examined the inhibitory activities of compounds that show inhibitory affinity for targeting T. 
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cruzi,
13-16, 18-21
 this data is readily available and can be employed to develop effective screening 
devices and gain insight into the inhibition mechanisms of the compounds.  
A pharmacophore was deduced from AIAs with high inhibitory affinities (Figure 1). The 
pharmacophore displays the importance of the rigid three ring system through the identification 
by hydrophobes. Three acceptor positions of these compounds also appear important; hence, the 
atoms surrounding the identified hydrophobes and acceptors of Figure 2 were used for the 
alignment of all compounds (Figure 3). PLS was then employed to construct predictive models 
that implemented experimental inhibitory data and respective three-dimensional compound 
conformations that were defined by the molecular descriptors used, CoMFA or CoMSIA. The 
four models developed were all statistically significant and validated accordingly (Tables 1 and 2 
and Figure 4). Although all models were shown to be useful predictive devices the models that 
are most optimal for predicting inhibitory activity accurately are: (1) the model employing 
CoMFA molecular descriptors and experimental inhibitory data acquired at 4°C, and (2) the 
model employing CoMSIA molecular descriptors and experimental inhibitory data acquired at 
37°C. This appeared to be counterintuitive until models were further examined; the other two 
models were much more rigid and this was reflected in predictions. Through the analysis of 
model predictions it was found that large deviations in predictions were acquired most often 
when the experimental values between the two assays were large. 
Molecular descriptor potentials were extrapolated from the models and used to gain 
insight about important structural contributions that may be employed to improve compound 
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design (Figures 5 and 6). The most useful data appears to be that which comes from the most 
optimal models that were previously identified. Steric and electrostatic molecular descriptors for 
the model employing CoMFA molecular descriptors and experimental inhibitory data acquired at 
4°C displayed that: (1) compounds can be elongated; (2) there is some room for modification of 
the isopropyl substituent region of reference compound DB766, although there appear to be 
some size limitations; and (3) positive charge is shown to be important to regions of N=C−N 
groups (Figure 5). This suggests that the pharmacophore identification of the positive nitrogen 
potential, and two donor potentials at the N=C−N groups, have some relevance to important 
inhibitory structure for treating blood stored at 4°C (Figure 1). Steric, electrostatic, hydrophobic, 
H-donor and H-acceptor molecular descriptors for the model employing CoMSIA molecular 
descriptors and experimental inhibitory data acquired at 37°C displayed that: (1) compounds can 
be elongated; (2) there is some room for modification of the isopropyl substituent region of 
reference compound DB766, although there appear to be some size limitations; (3) the outer 
hydrophobic rings appear to be of importance; (4) the addition of H-donors to p-position of the 
outer aromatic rings may lead to improved inhibitory compounds; and (5) H-acceptors are 
favored  at the N=C−N groups of reference structure DB766 (Figure 6).  
In summary, a pharmacophore for highly inhibitory compounds was identified, predictive 
devices for the screening of inhibitory activity at 4°C and 37°C were constructed for DA and 
AIA compounds, and molecular descriptor potentials have been extracted to determine structural 
importance as related to the design for novel therapeutics. Structural importance for inhibiting T. 
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cruzi was found to be an overall rigid conformation, similar to that of current AIAs, that has 
N=C−N groups. Areas for modifications have been identified as the p-position of the outer 
aromatic rings, isopropyl substituent regions of reference compound DB766, and central atoms 
of the AIAs. 
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Tables and Figures 
Table 1. Statistics of partial least squares predictive models for a biological dataset of synthetic 
diamidines and arylimidamides with activities against Trypanosoma cruzi at 4°C and 37°C. 
Models employ either CoMFA or CoMSIA molecular descriptors. The optimal N components 
were determined by the smallest predicted error sum of squares; N was determined to be optimal 
at 3, 4, 4, and 3 for models displayed from left to right, respectively. 
     CoMFA CoMSIA 
 4°C 37°C 4°C 37°C 
Q
2
 0.58 0.56 0.51 0.54 
SEE 0.27 0.28 0.16 0.26 
R
2
 0.94 0.95 0.98 0.95 
F 180 160 420 260 
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Table 2. Experimental and predicted pIC50 values for test set compounds. The name of the 
structure is displayed to the far left; this is followed by the structure, the experimental pIC50 
values at both 4°C and 37°C, and the predictions from the respective models employing CoMFA 
or CoMSIA molecular descriptors at the two temperatures. Diamidines have an overall +2 charge 
and arylimidamides have an overall +1 charge. 
DB613A
DB1627
14SMB013
10SAB031
DB1868
DB1362
Experimental CoMFA CoMSIA
4°C 37°C 4°C 37°C 4°C 37°C
-1.5 -1.5 -1.6 -1.7 -1.6 -1.7
-0.29 -0.61 -0.13 -0.36 0.48 -0.28
-0.85 -0.82 -0.66 -1.3 -0.05 -1.1
-1.5 -0.97 -1.3 -1.5 -1.0 -1.3
-1.5 -1.5 -1.1 -2.1 -0.33 -1.4
0.55 1.2 1.2 -1.2 1.3 -1.4
Name Structure
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Figure 1. GALAHAD potentials as identified by simulations employing four arylimidamide 
compounds (DB1831, DB1853, DB1868 and DB766, Supplemental Table 4, Appendix C) with 
high inhibitory affinity. The identified features are color coded: cyan, hydrophobes; magenta, 
donor atoms; green, acceptor atoms; red, positive nitrogens. 
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Figure 2. Alignment atoms identified on the arylimidamide DB766; these are color coded as in 
Figure 1. The atoms representative of the hydrophobes are in cyan and those of the acceptor 
atoms are in green. 
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Figure 3. The training dataset of 41 compounds (top) was employed to construct partial least 
squares regression models, whereas the testing dataset of 6 compounds (bottom) was employed 
to assess the models constructed.  
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Figure 4. Predictions for the training (blue and green) and testing (red) datasets are displayed 
with respect to experimental data. The data from models employing CoMFA molecular 
descriptors are on the left, whereas those using CoMSIA molecular descriptors are on the right. 
Experimental data for assays and respective predictions at 4°C are displayed above those at 
37°C. The trendlines for the training dataset predictions are displayed along with their respective 
equations and R
2 
values. 
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Figure 5. Potentials for models employing CoMFA molecular descriptors and biological pIC50 
values. Favored steric and positive electrostatic potentials are shown in green and blue, whereas 
disfavored potentials are displayed in yellow and red, respectively. DB766 is used as a reference 
compound; the data displayed are for the overall models. The models for inhibition at 4°C are 
displayed to the left of the models for inhibition at 37°C and the steric molecular descriptor 
potentials are shown above respective electrostatic potentials. 
4°C 37°C
Steric
Electrostatic
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Figure 6. Potentials for models employing CoMSIA molecular descriptors and biological pIC50 
values. Favored steric, positive electrostatic, hydrophobic, H-donor, and H-acceptor potentials 
are shown in green, blue, yellow, cyan, and magenta; negative potentials are displayed in yellow, 
red, white, purple, and red, respectively. As in Figure 5, DB766 is used as a reference compound 
and the data are displayed for the overall models. 
4°C 37°C
Steric
Electrostatic
Hydrophobic
H-Donor
H-Acceptor
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Tricyclic N-Methylpyrrole (Py) and N-methylimidazole (Im) containing polyamide 
monocations are known to bind as stacked dimers within the minor groove of DNA and those 
with N-terminal formamido (f) substituents bind in a staggered configuration with high 
specificity over a range of affinities. Although binding constants have been reported, there is not 
a clear understanding of why such constants vary significantly for polyamide dimers and their 
respective cognate DNA sequences. By employing computational tools, the following homo-
dimer complexes have been addressed in this study: f-PyPyIm in complex with 5’-
d(GAACTAGTTC)-3’, f-ImPyPy in complex with 5’-d(GAATGCATTC)-3’ and f-ImPyIm in 
complex with 5’-d(GAACGCGTTC)-3’. These complexes were selected based on their 10 to 
100-fold differences in binding constants. From this study, it was possible to determine how 
polyamides anchor themselves within the minor groove of specific DNA sequences. This is done 
through several interactions that provide stability for specific recognition: (1) Py groups secure 
themselves between DNA base pairs, (2) lone-pair-Π interactions are formed between DNA 
deoxyribose O4’ and Im groups nearest f, (3) minor groove bases hydrogen bond to Im groups 
and amides of the polyamide backbone, (4) the f substituents rotate without leaving the minor 
groove of DNA and with this rotation form specific hydrogen bonds with electron rich sites on 
the floor of the minor groove, and (5) flexible charged N,N-dimethylaminoalkyl substituents 
reside favorably in the minor groove of DNA. Results displayed the greatest amount of 
interactions and stability for dimer f-ImPyIm in complex with 5’-d(GAACGCGTTC)-3’ and the 
least amount in dimer f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’. Hence, for cognate 
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DNA sequences, the relative binding strength of compounds was determined as f-ImPyIm > f-
ImPyPy > f-PyPyIm. This force-field-based computational study is in agreement with 
experimental results and provides a molecular rational for the binding constant values.  
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Introduction 
 The antibiotics netropsin and distamycin A, along with synthetic, tricyclic N-
methylpyrrole (Py) and N-methylimidazole (Im) polyamides, bind within the minor groove of 
cognate DNA sequences with high specificity but with a surprisingly wide range of affinities 
(10
5 
M
-1
 to 10
8
 M
-1
).
1, 2
 The binding sequence specificity of these compounds follows a well-
defined set of rules that have been established and confirmed via experimental techniques.
1, 3-5
 
Polyamide compounds align anti-parallel within the minor groove, tail-to-head and head-to-tail, 
to form stacked dimers able to recognize specific base pairs: Py overlapped with Py (Py-Py) 
recognizes adenine (A) thymine (T) base pairs or TA base pairs, Im overlapped with Im (Im-Im) 
recognizes guanine (G) cytosine (C) base pairs or CG base pairs, Im overlapped with Py (Im-Py) 
recognizes GC, and Py overlapped with Im (Py-Im) recognizes CG. These relationships are 
displayed visually through experimental findings, including X-ray diffraction
5-7
 and NMR,
7, 8
 for 
complexes of Im- and Py-containing polyamides with duplex oligodeoxyribonucleotides. As a 
result of their ability to recognize specific DNA sequences, polyamides are being developed as 
potential gene control agents with applications in cancer treatment as well as biotechnology.
9-14
  
 Experimental studies have uncovered two structural components of polyamide dimers 
that significantly affect DNA binding affinity: the N-terminal formamido group (f) and the 
combination and order of the pyrrole and imidazole moieties.
1, 2, 6, 8, 15-22
 Compared to non-
modified polyamides, those with an N-terminal f substituent displayed increased affinity for 
sequence specific binding within the minor groove.
1, 2
 This general trend can be illustrated with 
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results for ImPyPy and f-ImPyPy. The binding affinity of f-ImPyPy (Figure 1) with cognate 
DNA increased by approximately 10
2
 M
-1
 compared to ImPyPy with cognate DNA when a 
terminal f was present. The association and dissociation rates were slower for the f derivative and 
the polyamide stacking mode for the complex with f compounds were staggered while the others 
were overlapped.
2
 Similar results have also been observed for other non-modified and f modified 
polyamides with their respective cognate DNA sequences.
1, 2
  
 In silico docking and molecular dynamics studies have also provided valuable insight into 
DNA-polyamide, and other compound, interactions.
23-27
 For example, the flexible β-Dp tails of 
the ImHpPyPy-β-Dp polyamides contributed to binding through water mediated contact with 
phosphate oxygen.
28
 Docking studies have also aided in the construction of DNA-polyamide 
complexes to examine the movements and interactions of individual bases, such as the roll of 
base pairs when computationally constructed polyamides were examined in complex with 
DNA.
24, 29
 Experimental thermodynamic data have been examined through limited docking of f-
ImPyIm (Figure 1) polyamides.
17
 
 The unanswered fundamental question in the experimental studies is why the 
combination and arrangement of Py and Im moieties have such a significantly different effect on 
binding affinity with cognate DNAs.
1, 18
 Given these observed differences, analyzing 
experimental binding constants with regard to molecular structure interactions of DNA-
polyamide complexes can provide valuable insight. The goal of this study is to use in-depth 
docking methods to compare and examine how polyamides interact with DNA structure and 
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groups in the minor groove. Through the use of computational tools, several complexes were 
examined: f-PyPyIm in complex with cognate sequence 5’-d(GAACTAGTTC)-3’, f-ImPyPy in 
complex with cognate sequence 5’-d(GAATGCATTC)-3’, and f-ImPyIm in complex with 
cognate sequence 5’-d(GAACGCGTTC)-3’. These complexes have experimentally determined 
binding constants of 1 × 10
6
, 1 × 10
7
, and 2 × 10
8 
M
-1
, respectively.
1, 18
 This study represents the 
first in-depth docking approach to examine these polyamides and their cognate sequences to 
address the experimental affinity variations. Significant differences were found between the 
strongest and weakest binding polyamide dimers. 
Experimental Procedures 
 Polyamides f-PyPyIm, f-ImPyPy, and f-ImPyIm were previously synthesized and 
examined in complex with 5’-d(GAACTAGTTC)-3’, 5’-d(GAATGCATTC)-3’, and 5’-
d(GAACGCGTTC)-3’, respectively. Surface plasmon resonance (SPR) was employed to 
determine binding constants.
1, 18
  
 Docking Preparation. The three polyamide-DNA complexes were evaluated by 
employing SYBYL 8.1
30
 software on a Fedora Core 5 Linux Workstation. Solution nuclear 
magnetic resonance (NMR) structure 1B0S
31
 was obtained from the protein data bank; this 
structure was used as a template and as a reference complex. 1B0S, an f-ImImIm dimer in 
complex with 5’-d(GAACCGGTTC)-3’, was mutated using the Biopolymer and Building and 
Editing modules in SYBYL to form: the f-PyPyIm dimer in complex with 5’-
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d(GAACTAGTTC)-3’, the f-ImPyPy dimer in complex with 5’-d(GAATGCATTC)-3’, and the 
f-ImPyIm dimer in complex with 5’-d(GAACGCGTTC)-3’. These modified complexes were 
then minimized for 100 iterations using the Tripos force field; thus, allowing the somewhat rigid 
DNA to accommodate the mutated bases and polyamides through slight changes to the width of 
the minor groove. Polyamide dimers were then moved to second memory locations, separate 
molecular areas within the SYBYL graphical user interface. The ability to move, or rather 
extract, the compounds into a separate molecular area allowed the compounds to explore 
torsional angles, translation, and rotational angles independent of the DNA when the FlexiDock 
genetic algorithm was employed. The two compounds of the dimer were given torsional, 
translational, and rotational freedom independent of each other; yet, they were docked 
simultaneously into the DNA. The structures of the polyamides are displayed in Figure 1.  
 The FlexiDock module of the SYBYL software suite was then implemented. Ten 
different random starting locations were assigned and employed by the genetic algorithm one at a 
time for a total of ten docking trials. Calculated and assigned as in previous studies, the large 
amount of generations ensured that lowest energy conformations were obtained.
32, 33
 Each 
docking trial consisted of 516 000 generations. The dimers and the DNA were permitted 
torsional, rotational, and translational flexibility throughout the docking process. Atomic charges 
for the DNA were calculated using the Kollman All-Atom protocol, while the dimer was 
assigned Gasteiger-Huckel charges. All possible hydrogen bonding sites on the dimer and 
cognate DNA were targeted for function where possible. From each docking the 20 lowest 
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energy structures were selected. Hence, 200 structures were produced for each complex 
examined; 10 random starting locations × 20 low energy structures from each docking. The 
energy values (EMM) for the overall lowest energy complexes are displayed in Table 1.  
 Docked Structure Analyses. Interactions were calculated and viewed using modules and 
tools of the SYBYL software package. The FlexiDock module optimizes torsional angles, 
translation, and rotational angles to minimize the energy function. Compounds were examined 
using the FlexiDock scoring function, which is based on the Tripos force field and estimates the 
energy for the dimer, the receptor, and the complex. The score is evaluated with van der Waals, 
electrostatic, torsional, and hydrogen bonding energies; lower energy in the complex state 
suggests better binding. Hydrogen bond distances were analyzed using the “Display H-Bonds” 
and “Measure” options. Values obtained were averaged for the 20 lowest energy conformations 
of each complex. All measurements were from heavy atom to heavy atom. The 40 lowest energy 
complex conformations displayed variations of the f group. The Advanced Computation and 
Dock modules, of the SYBYL software suite, were employed to gain further explanation into the 
Im and Py similarities and differences with respect to electrostatics and dipoles.  
 Grid Search, an application of the Advanced Computation module, was used to examine 
the f groups, of the lowest energy conformation of each complex, in Cartesian space through 
systematic rotation about bonds using defined increments of 20ᴼ for a total of 360ᴼ. At each 
increment the torsional bond angle was constrained and the conformation was minimized. The 
minimization of complexes employed default parameters.
30
 This allowed for a systematic 
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exploration of torsional freedoms with regard to respective energies. These complexes were then 
arranged by f group rotation in increments of 20ᴼ and then averaged so that the general trend of 
the energies could be viewed, analyzed, and compared effectively.  
 The Dock module of SYBYL 7.3
34 
was then employed to re-examine structures and 
calculate energy values for low energy complexes obtained via FlexiDock and Grid Search. This 
software was ideal since structures could be observed and energy values could be calculated 
without changes to DNA-polyamide complex conformations.  
 Accessible solvent area (ASA) was examined for each lowest energy complex with 
Chimera software.
35
 The module employed was the Area/Volume from Web (StrucTools server) 
with calculation options Gerstein ASA, surface probe 1.4 and all atoms except water. ASA was 
acquired for each complex, DNA, and individual polyamide. The ASA was summed for each 
atom of each residue and polyamide.  
 The Spartan ’0436 software package was employed to examine geometry optimized Py 
and Im groups using a single point ab initio calculation employing the Hartree-Fock 6-31G** 
level. This allowed for comparisons of ab initio calculated electrostatic potential maps and 
dipoles. 
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Results 
 The modification of NMR solution structure 1B0S resulted in the construction of the f-
PyPyIm dimer in complex with 5’-d(GAACTAGTTC)-3’, the f-ImPyPy dimer in complex with 
5’-d(GAATGCATTC)-3’, and the f-ImPyIm dimer in complex with 5’-d(GAACGCGTTC)-3’. 
Each of the polyamides underwent extensive docking, as did reference polyamides from 1B0S, 
within their respective DNAs to yield optimized structures. 
 Reference complex, 1B0S, displayed only slight deviations from the refined average 
structure obtained via solution NMR. The calculated root mean squared error between the NMR 
structure and the lowest energy docked structure was approximately 0.60. Figure 2 displays the 
alignment of the 10 lowest energy 1B0S-docked reference structures.  
 f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’. The low energy structures of f-
PyPyIm are hydrogen bonded as a staggered dimer to 5’-d(GAACTAGTTC)-3’ (Figure 3). The 
base pairs involved in hydrogen bonding include those within the center of the DNA, 5’-
d(ACTAGT)-3’, the AT base pair followed by CG, TA, AT, GC, and TA, respectively. Each 
image of Figure 2 (Right) was taken as the DNA was rotated to the right, so that the bases would 
take on a view that was as linear as possible. 
 The hydrogen bond displayed in the top AT base pair is between the upper dimer 
compound amide NH of the charged polyamide tail and the C2 O of the T base. Both of the 
hydrogen bonds displayed in the following image of CG also exist between the upper compound 
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of the dimer and the G base subsequent to the T on the same DNA chain. The hydrogen bonds 
are between the Im N and the G C2 NH2 and between the following amide NH and the G N3. 
Because of the staggered stacking, the TA base pair represents the first image in which 
heterocycles from both compounds of the dimer are present and both are hydrogen bonding. In 
this image the upper dimer compound amide NH following the Py is forming a hydrogen bond 
with the A N3, while the lower compound of the dimer is forming a hydrogen bond between the 
amide NH above the Py and the T C2 O. The image of AT and the dimer compounds also 
displays both compounds forming hydrogen bonds to respective DNA bases. The upper 
compound amide NH is hydrogen bonded to the T C2 O, while the lower compound amide NH is 
hydrogen bonded to the A N3. The following image displays base pair GC which hydrogen 
bonds with the lower dimer compound. The amide NH prior to the Im is hydrogen bonded to G 
N3 and the Im N is hydrogen bonded to the G C2 NH2. The TA base pair, of the last image, is 
similar to the first base pair AT. In this region the NH following the Im of the lower dimer 
compound hydrogen bonds to the T C2 O. 
 f-ImPyPy in complex with 5’-d(GAATGCATTC)-3’. Docking results display f-ImPyPy to 
be hydrogen bonded more favorably to 5’-d(GAATGCATTC)-3’ (Figure 4) than the f-PyPyIm 
dimer described above. Further stabilization is obtained from lone-pair-Π interactions between 
DNA deoxyribose O4’ and the Im groups of the dimer polyamides. Similar to the compounds 
observed in Figure 3, f-ImPyPy is bound in a staggered dimer conformation and the base pairs 
involved in hydrogen bonding include those within the center of the DNA, in this case 5’-
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d(ATGCAT)-3’. The images of Figure 4 (Right) show the AT base pair followed by TA, GC, 
CG, AT, and TA. 
 The hydrogen bonds displayed in the top AT base pair region are between the upper 
compound amide NH of the charged polyamide tail and the C2 O of the T base and between the 
upper compound amide NH and the lower compound f O. The hydrogen bond displayed in the 
following image of TA exists between the upper compound amide NH subsequent to the Py and 
the A N3. The GC base pair represents the first image in which both compounds of the dimer are 
visible and both are partaking in hydrogen bonding. In this image the upper dimer compound 
amide NH following the Py is forming a hydrogen bond with the C C2 O, while the lower 
compound of the dimer is forming hydrogen bonds between the f amide NH and the G N3 and 
the Im N and the G C2 NH2. The image of CG and the dimer compounds also displays both 
compounds forming hydrogen bonds to respective DNA bases. The upper compound Im N is 
hydrogen bonded to the G C2 NH2 and the following amide NH is hydrogen bonded to the G N3. 
The lower compound amide NH is hydrogen bonded to the C C2 O. The following image 
displays base pair AT. Hydrogen bonds displayed in this base pair region exist between the 
compounds of the dimer and between the lower compound amide NH, above the Py, and the A 
N3. The last image, of the TA base pair, displays a single hydrogen bond between an amide NH 
and the T C2 O. 
 f-ImPyIm in complex with 5’-d(GAACGCGTTC)-3’. Docking results display the f-
ImPyIm dimer to be hydrogen bonded to 5’-d(GAACGCGTTC)-3’ (Figure 5) even more 
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favorably than either of the previous dimers to their cognate sequences. Similar to what was seen 
in Figure 4, Figure 5 shows stabilization in lone-pair-Π interactions between DNA deoxyribose 
O4’ and the Im group nearest the f of the polyamides. As seen in Figures 3 and 4, these 
compounds take on a staggered dimer conformation and the base pairs involved in hydrogen 
bonding include those within the center of the DNA, in this case 5’-d(ATGCAT)-3’. As 
displayed in Figure 3 and 4, the images of Figure 5 (Right) show the AT base pair followed by 
TA, CG, GC, CG, GC, and TA.  
 The hydrogen bond displayed in the top AT base pair region is between the upper 
compound polyamide charged tail amide NH and the C2 O of the T base. Four hydrogen bonds 
exist in the following image of CG. These hydrogen bonds are between the upper compound 
amide NH and lower compound f O, between the upper compound Im and the G C2 NH2, 
between the amide NH subsequent to the Im of the upper compound to the G N3 and between the 
f O of the lower compound and the G C2 NH2. The GC base pair represents the first image in 
which both compounds of the dimer are present and both are partaking in hydrogen bonding to 
both strands of the DNA. In this image the upper dimer compound amide NH following the Py is 
forming a hydrogen bond with the C C2 O, while the lower compound of the dimer is forming 
hydrogen bonds between the amide NH and the G N3 and the Im N and the G C2 NH2. The 
image of CG and the dimer compounds also displays both compounds forming hydrogen bonds 
to respective DNA bases. The upper compound Im N is hydrogen bonded to the G C2 NH2 and 
the following amide NH is hydrogen bonded to the G N3. The lower compound amide NH is 
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hydrogen bonded to the C C2 O. The following image displays base pair GC. Similar to the first 
CG region, four hydrogen bonds are displayed in this base pair region. These hydrogen bonds are 
between the upper compound f O and lower compound amide NH, between the lower compound 
Im N and the G C2 NH2, between the amide NH prior to the Im of the upper compound to the G 
N3 and between the f O of the upper compound and the G C2 NH2. The last image, of the TA 
base pair, displays a single hydrogen bond between an amide NH and the T C2 O. 
 Terminal Interactions. Overall docking results for all three complexes display significant 
flexibility in the polyamide charged tails, as expected, and significant rotation of the f 
substituent, which provides unexpected extra insights, while the heterocycles and amide groups 
exhibit less flexibility. As noted above, the charged tail amide NH forms hydrogen bonds to T 
C2 O base pairs (Figures 3, 4, and 5). The remainder of each polyamide charged tail resides 
favorably within respective cognate DNA minor grooves. Rotation of the f group allows for 
different hydrogen bonds to form and stabilize the complex. Figure 6 displays such changes 
within overlaid lowest energy structures of f-ImPyIm in complex with 5’-d(GAACGCGTTC)-3’. 
The lowest energy structure, previously addressed in Figure 5, is shown as caped sticks, while a 
second low energy conformation is displayed as ball and stick structures. The f NH of the most 
common lowest energy structures obtained from docking displays hydrogen bonds to G N3 of 
the first GC base pair of the recognition sequence (Figures 5 and 6, Upper Right); however, upon 
rotation of f this interaction is lost and new hydrogen bonds are formed between the f O and the 
G C2 NH2 of the first CG base pair and the G C2 NH2 of the first GC base pair (Figure 6, Lower 
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Right). When this rotation occurs the hydrogen bond between the dimer polyamides, f O and 
charged tail NH, can no longer form. The rotation of f can occur at either end of the dimer 
formation. These formations, obtained via FlexiDock, were analyzed further through Grid 
Search. Figure 7 displays the energy fluctuations as rotation occurs in the f group. In the plot, the 
lowest energy complex conformations, with respect to f torsional angles, are for the two 
hydrogen bonded conformations in Figure 6. 
 Complex Energies. Relative total energies for lowest energy complexes subsequent to 
FlexiDock and Grid Search, calculated via Dock, are reported in Table 2. Total energies are the 
sum of steric and electrostatic energies. For complexes from FlexiDock, the steric and 
electrostatic energies are respectively, -23.5 and -56.6 kcal/mol for the complex with dimer f-
PyPyIm; -73.9 and -44.9 kcal/mol for the complex with f-ImPyPy; and -77.9 and -52.4 kcal/mol 
for the complex with dimer f-ImPyIm. For each complex acquired via Grid Search the steric and 
electrostatic energies are respectively, -75.3 and -28.0 kcal/mol for the complex with dimer f-
PyPyIm, -75.3 and -42.6 kcal/mol for the complex with f-ImPyPy, and -72.7 and -53.3 kcal/mol 
for the complex with dimer f-ImPyIm. Since the 180° rotation of f occurred in the top twenty 
percent of lowest energy complexes, as viewed in Figure 6, energies for these complexes were 
also calculated subsequent to Grid Search (Table 2). For each complex acquired steric and 
electrostatic energies are respectively, -72.6 and -26.8 kcal/mol for the complex with dimer f-
PyPyIm, -72.4 and -44.8 kcal/mol for the complex with f-ImPyPy, and -73.6 and -52.6 kcal/mol 
for the complex with dimer f-ImPyIm. 
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 Accessible Surface Area (ASA). Buried surface on complex formation was addressed 
through ASA calculations. Figure 8 displays the surfaces for the complexes, DNA and 
polyamides; blue surfaces encompass positively charged regions, while red cover those that are 
negatively charged. Positive and negative regions of the polyamides can align with those of the 
DNA minor groove to maximize electrostatic interactions. This was further supported with the 
ASA values for the complexes, DNA and polyamide (Figure 9). The red area represents the 
DNA. Notice that the DNA ASA is fairly similar for all three complexes, as are the three 
polyamide areas displayed in green. The blue areas show differences related to the respective 
DNAs binding their specific polyamides for complex formation: (1) the complex with f-PyPyIm 
displays more ASA at the T bases of the recognition sequence than the other two complexes, (2) 
the complex with f-ImPyPy displays a decreased ASA near the A bases of the recognition 
sequence, and (3) the complex with f-ImPyIm is the most uniform and consists of the most 
buried ASA. 
 Ab Initio Electrostatic Potential Maps. To understand the energy contributions from 
polyamide structures, it is informative to compare the ab initio calculated electrostatic potential 
maps for the Py, Im, and amide units of the polyamide dimers (Figure 10) with each other as well 
as with the low energy stacked complexes shown in Figure 11. Although the dipole moments of 
the Py and Im heterocycles point in the same direction, the magnitude of the dipole is larger for 
the Im and the electrostatic potential maps clearly show a significantly different distribution of 
molecular electrostatic potential.  With both the Py and Im the positive potential is distributed on 
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the N-Me group and close vicinity. With the Py the highest negative potential is on the Py Π-
system while in the Im, it is on the unprotonated Im-N (Figure 10). As expected, the negative 
potential on the amide is highest on the carbonyl O while the positive potential is on the -NH. 
With this distribution, the dipole moment of the amide points in the opposite direction to the 
heterocycles (Figure 10) in the orientation of DNA binding (Figure 11). 
 Each of the stacked polyamides has six heterocycles that can be evaluated in terms of the 
maps in Figure 10.  Starting with the weakest binder, f-PyPyIm (Figure 11), the heterocycles 
interact as follows: At top of the Figure, (1) the first Im is relatively unstacked; (2) the next 
heterocycle (lower molecule of the dimer) is stacked favorably with a positive amide -NH over 
the negative area of the pyrrole; (3) the next two pyrroles are stacked such that their positive 
regions are near negative carbonyl O atoms, a fairly favorable orientation; (4) The next Py has its 
most positive region closely stacked with a positive -NH, an unfavorable interaction; and (5) the 
last Im is not well stacked. In the strongest binding f-ImPyIm complex (Figure 11), (1) the first 
Im is not strongly stacked; (2) the next Im (lower molecule) is favorably stacked with an amide 
with the negative carbonyl O of the amide near the most positive region of the Im (Figure 10) 
and the amide positive H of the -NH stacked near the negative Im-N; (3) the next two Py groups 
are also favorable stacked with amide negative O atoms near their positive N-Me groups; (4) the 
next Im is in a similar favorable orientation with an amide O near the positive N-Me of the 
imidazole while the positive H of the amide -NH is near the Im negative N; and (5) the last Im is 
not as strongly stacked as the internal heterocycles. It should be noted, however, that the terminal 
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two Im groups are stacked with their most negative regions near the most positive regions of the 
adjacent Ims and, given the larger dipole moment of the Im versus Py groups (Figure 10), this 
should be a favorable contribution. In summary, the electrostatic interactions between the 
stacked heterocycles appear to make favorable contributions to dimer binding of both f-PyPyIm 
and f-ImPyIm but there are more and stronger favorable interactions in the f-ImPyIm dimer. 
Discussion 
 Experimental results for simple tricyclic polyamides, such as those in Figure 1, have a 
puzzling, large variation in energies when bound by their cognate DNA sequences.
1, 2
 We have 
conducted a docking study for the polyamides of Figure 1 and respective cognate DNA to 
provide some initial molecular level information on the different complexes. Three components 
that contribute to polyamide dimer-DNA interactions were investigated in the docked structures: 
(1) hydrogen bonding, (2) buried surface on complex formation, and (3) electrostatic interactions 
of the polyamide units in the stacked dimer. All of these interactions have been evaluated and 
these results provide insight into the large variations in binding constants. 
 When analyzing the dimer of f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’ and its 
resulting position due to interactions with the minor groove, it is important that the dimer overlap 
is a staggered conformation of central Py-Py/Py-Py (Figures 3 and 11). The stacked Py groups 
form a stable motif with the ability to anchor these polyamides into stable dimer conformations 
in the minor groove (Figures 2). Figure 12 illustrates the models from Figure 3 in two-
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dimensions and shows the interactions of the Py-Py stacked motif with the central base pairs of 
the cognate binding sequence. The Py groups fit between the bases and aid in position indexing 
so that amide NH groups and the Im N can form favorable hydrogen bonds with base functional 
groups. The electrostatic potentials also play a significant role in both the specific interactions 
and complex stabilization (Figures 8 and 9).   
 The f-ImPyPy dimer polyamides also overlap in a staggered conformation of Py-Im/Im-
Py (Figures 4 and 11). As in Figure 3, steric interactions of the stacked Py groups appear to play 
an important role in anchoring these polyamides within their recognition sequence. Py groups 
index themselves with steric complementary between the base pairs. The Im groups form 
favorable hydrogen bonds, due in part to the added stability provided by the steric positioning 
interactions of the Py groups. The optimum positioning of the Py and Im groups allows the dimer 
to form hydrogen bonds between the ends of the upper and lower stacked compounds in Figures 
4 and 13. Polyamide f-ImPyPy, in complex with 5’-d(GAATGCATTC)-3’, displays stacking 
differences that vary from those of f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’ and 
these appear to be due to electrostatic interactions between the polyamides and the DNA (Figures 
8, 10, and 11). DNA and polyamides were mobile throughout the docking process; the f-ImPyPy 
polyamides moved into minor groove regions that are more optimal than those of the f-PyPyIm 
complex (Figures 4 and 13). This allows for more favorable interactions and a larger negative 
calculated energy, EMM (Table 2).  
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 Similar to f-PyPyIm and f-ImPyPy dimers, f-ImPyIm polyamide dimers overlap in their 
minor groove location in a staggered conformation of Py-Im/Im-Py (Figures 5 and 14). As seen 
in Figures 3 and 4, the Py groups index themselves between base pairs with steric 
complementary and play an important role in anchoring the compound into stable low energy 
docked conformations with the best possible positioning. The Im groups contribute to the GC 
base pair recognition and general affinity. The optimum positioning of the Py and Im groups also 
allows the dimer to form hydrogen bonds between the charged N,N-dimethylaminoalkyl tail NH  
of the upper compound and the f O of the lower compounds. The Im groups on the ends also 
contribute significantly to the amount of hydrogen bonding. This is by far the most stable of the 
three structures evaluated, as shown by the wealth of hydrogen bonding and the positioning of 
the compounds. The terminal Im, not involved in the Py-Im/Im-Py stacking, forms tight 
hydrogen bonds and the compounds are pulled in close to the DNA. These interactions are 
enhanced by favorable electrostatic interactions that reduce the ASA (Figures 8 and 9). The 
DNA and compounds form tight favorable interactions and the EMM value for the complex with 
f-ImPyIm is more negative than the values obtained for complexes with compounds f-PyPyIm or 
f-ImPyPy. 
 Given that the compounds of the dimer are binding to the same sequences on opposite 
DNA strands one may expect the hydrogen bonds to be quite similar. The small differences in 
observations of individual structures are as expected for flexible docking. The complex with f-
PyPyIm does not exhibit hydrogen bonding between the two compounds of the dimer and these 
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compounds exhibit more mobility within the DNA minor groove (Figures 3 and 12). The 
hydrogen bond length similarities in compound binding to respective DNA strand are only found 
in two locations, at the terminal T and the center A of recognition sequence 5’-d(ACTAGT)-3’. 
The complex with f-ImPyPy exhibits hydrogen bonding within the dimer, at both ends of the 
compounds, and this results in a greater amount of consistent hydrogen bond length similarities 
between compounds and their respective DNA strands (Figures 4 and 12). The hydrogen bond 
length similarities in compound binding to respective DNA strand are found in three locations 
central the recognition site, at the G, C, and A of recognition sequence 5’-d(ATGCAT)-3’. The 
complex with f-ImPyIm exhibits hydrogen bonding within the dimer and to the bases of the 
parallel DNA strand (Figures 5 and 14). The hydrogen bond length similarities in compound 
binding to respective DNA strands are found throughout the recognition site, at the G, C, G, and 
T of recognition sequence 5’-d(ACGCGT)-3’. 
 The terminal groups of the polyamides are flanked by a flexible charged tail and a small f 
substituent. The movements of the charged N,N-dimethylaminoalkyl tail were minor in 
comparison to a previous molecular dynamics study examining polyamides with longer tails.
28
 
The charged N resided toward the center of the minor groove between the phosphates of the 
DNA backbone. Perhaps, possible interactions with phosphates are limited by the size of the tail 
and the stable hydrogen bonding of the tail NH with T C2 O.  
 The rotation of the f group in the stacked complexes is a significant observation in these 
experiments. The terminal f substituents are small enough to rotate in the dimer widened minor 
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groove without the polyamide leaving the minor groove and energies obtained suggest that the 
two orientations shown in Figure 6 contribute to binding (Figures 6, 7, and Table 2). The steric 
contributions to energy are similar, most likely due to the similar size of all three polyamides and 
the areas occupied; electrostatics differ much more. It is also important to note that stability of 
structures resulted in consistency of EMM values, even when f rotated 180ᴼ. These results suggest 
that when a single polyamide begins to deviate from its recognition site, a rotation of f occurs 
and new bonds are formed; thus, keeping the complex longer than if the f substituent was absent. 
This discovery explains our recent observations that modifications of the f group with other acyl 
groups results in diminished binding affinity.
22
 Specifically, the order of binding constants was f-
ImPyIm >> Acetyl-ImPyIm > N-methylureidoacetyl-ImPyIm > trifluoroacetyl-ImPyIm. This is 
consistent with the suggestion that small and planar N-terminus subsitituents promote favorable 
binding with DNA. Furthermore, consistent with the role of the f or acyl group, ImPyIm analogs 
bearing an NH2 at the N-terminus and non-formamido-ImPyIm gave the weakest binding 
indicating the importance of having an f group to form favorable hydrogen bonds with sites on 
the floor in the minor groove. 
 Previously, experimental studies employing surface plasmon resonance (SPR) acquired 
binding constants for f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’, f-ImPyPy in complex 
with 5’-d(GAATGCATTC)-3’, and f-ImPyIm in complex with 5’-d(GAACGCGTTC)-3’; these 
constants are approximately 1 × 10
6
, 1 × 10
7
, and 2 × 10
8 
M
-1
, respectively.
1, 18
 In our studies, 
EMM values were calculated for the lowest energy complexes obtained via FlexiDock and Grid 
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Search (Table 2); the more negative the value, the stronger the binding. Both the experimental 
and the in silico data are in agreement. The ranked binding from strongest to weakest is: f-
ImPyIm in complex with 5’-d(GAACGCGTTC)-3’ > f-ImPyPy in complex with 5’-
d(GAATGCATTC)-3’ > f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’. 
 This in-depth docking approach provides useful new molecular information about 
polyamide complexes and how they are anchored within the minor groove. Hydrogen bonding, 
steric and electrostatic interactions all play a role, along with compound conformation, to 
determine how a compound will recognize specific DNA sequences. Specifically, f-ImPyIm 
binds better than the other dimers as a result of the greater amount of intra-dimer and intra-
complex hydrogen bonds, lone-pair-Π interactions, optimum dipole interactions, as well as 
excellent steric fit and electrostatic interactions. We are currently employing these findings to 
improve compound design. Findings suggest that dimer spacing provided by Py groups and 
hydrogen bonding interactions of Im groups can be employed to recognize even longer DNA 
sequences. This of course is given that recognition compounds: (1) keep a curvature that 
parallels that of DNA, (2) stack efficiently maintaining electrostatic interactions, and (3) have the 
ability to form hydrogen bonds on both ends. Insights from this study suggest that compounds 
such as f-ImPyImPyIm should bind and recognize 5’-d(-ACGCGCGT-)-3 with similar affinity 
and greater specificity than f-ImPyIm binds and recognizes 5’-d(GAACGCGTTC)-3’. These 
studies are in progress and the results will be reported in due course. 
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Tables and Figures  
Table 1. Energies (EMM) gained from FlexiDock docking studies. These values are in kcal/mol. 
  EMM 
f-PyPyIm with 5’-d(ACTAGT)-3’ -594 
f-ImPyPy with 5’-d(ATGCAT)-3’ -670 
f-ImPyIm with 5’-d(ACGCGT)-3' -765 
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Table 2. Total energies, reported as EMM values, gained from Dock for the lowest energy 
complexes obtained via FlexiDock and Grid Search. The EMM values for both low-energy 
structures acquired via Grid Search are labeled 1 and 2, respectively. Grid Search 1 relates to the 
structures with the f positioned as in the top right image of Figure 6, while Grid Search 2 relates 
to the structures with the f positioned as in the bottom right image of Figure 6.  All EMM values 
are in kcal/mol.  
  FlexiDock Grid Search 1 Grid Search 2 
f-PyPyIm with 5’-d(ACTAGT)-3’ -80.1 -103 -99.4 
f-ImPyPy with 5’-d(ATGCAT)-3’ -119 -118 -117 
f-ImPyIm with 5’-d(ACGCGT)-3' -130 -126 -126 
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Figure 1. Two-dimensional illustration of polyamide structures (Left) with abbreviations (Right): 
formamido (f), N-methylpyrrole (Py) and N-methylimidazole (Im). Dimer complexes of these 
compounds are shown docked into cognate DNA sequences in Figures 3-5. 
f-PyPyIm
f-ImPyPy
f-ImPyIm
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Figure 2. Overlay of the 10 lowest energy structures for the docking of reference structure, 1B0S, 
polyamides into cognate DNA. The refined average structure obtained from the protein data bank 
is displayed in green, while all other low energy complexes are displayed by atom type. 
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Figure 3. f-PyPyIm in complex with 5’-d(GAACTAGTTC)-3’. For clarity, the terminal bases are 
not displayed in the images and the images are of only the lowest energy conformation. The 
image on the left displays the complex as a whole, while the segmented images on the right show 
the individual bases as the polyamide-DNA complex is rotated to the right. Magenta arrows are 
displayed on the left image; these point to the Py groups. On the right, the bases are labeled in 
green, the hydrogen bonds are in white and the average respective hydrogen bond lengths are in 
yellow. Notice that the Py groups index themselves with steric complementary between base 
pairs, this is pointed out on the left and more clearly viewed in the central TA and AT images on 
the right. 
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Figure 4. f-ImPyPy in complex with 5’-d(GAATGCATTC)-3’. For clarity, the terminal bases are 
not displayed in the images and the images are of only the lowest energy conformation. The 
image on the left displays the complex as a whole and identified lone-pair-Π interactions 
(orange), while the segmented images on the right show the individual bases as the polyamide-
DNA complex is rotated to the right (labeled as in Figure 3).  
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Figure 5. f-ImPyIm in complex with 5’-d(GAACGCGTTC)-3’. For clarity, the terminal bases 
are not displayed in the images and the images are of only the lowest energy conformation. The 
image on the left displays the complex as a whole, while the segmented images on the right show 
the individual bases as the polyamide-DNA complex is rotated to the right (labeled as in Figures 
3 and 4).  
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Figure 6. f-ImPyIm in complex with cognate sequence 5’-d(GAACGCGTTC)-3’. The image on 
the left displays the overlap of the two low energy dimer conformations in the minor groove of 
the lowest energy DNA base pairs affected by f rotation. In an enlarged view for clarity, the 
images on the right display the two low energy conformations individually. These conformations 
consist of different hydrogen bonding interactions, which are shown in green. The upper right 
image displays the f N hydrogen bonding to the G N3 of the first GC base pair of the recognition 
sequence; whereas the lower right image displays the hydrogen bonding of f O to the G C2 NH2 
of the first CG base pair, as well as the G C2 NH2 of the first GC base pair. 
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Figure 7. Polyamide structure (Left) with an arrow pointing to the bond rotated via Grid Search. 
X represents N-methylpyrrole (Py) and/or N-methylimidazole (Im) depending on the complex 
employed for formamido (f) bond rotation. The graph (Right) displays the averaged, normalized 
energy values for each structure obtained after a 20ᴼ rotation of one or both f bonds within the 
dimer. Data for complexes with f-PyPyIm, f-ImPyPy, and f-ImPyIm, are displayed in blue, red 
and green, respectively. The lowest energy conformations are at 0ᴼ and 180ᴼ. At 0ᴼ the f is 
positioned as in Figure 6, Upper Right, and position 180ᴼ is shown in Figure 6, Lower Right. 
  
N
o
rm
al
iz
ed
 E
n
er
g
y
Degree of Rotation
0.6
0.8
1
0 90 180 270 360
 158 
 
 
Figure 8. Surfaces displaying electrostatic potentials with respect to coulombic coloring for the 
complexes (Left), DNA (Center) and polyamides (Right); blue surfaces encompass positively 
charged regions, while red cover those that are negatively charged. 
f-PyPyIm
f-ImPyPy
f-ImPyIm
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Figure 9. Accessible Surface Area (ASA) calculated for each base pair and polyamide in 
complex (blue) and alone (red for DNA and green for single polyamide). The ASA is reported in 
Å
2
 and the DNA bases are denoted as dA, dT, dG and dC for adenine, thymine, guanine and 
cytosine, respectively. Orange and purple lines spanning the three ASA graphs separate the two 
DNA strands and the polyamides. Both DNA strands are shown from 5’ to 3’, displaying the 
differences in each strand with (blue) and without (red) compound interaction. Yellow boxes 
highlight the specific recognition sites for each complex. The polyamides are displayed as L1 
and L2. When analyzing only a single polyamide (green), this compound is L1. 
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Figure 10. Ab initio calculated electrostatic potential maps for the Py, Im and amide units of the 
polyamide dimers, respectively these units are shown on the left with their dipole moments. The 
electrostatic potentials are shown in the center, blue is positive and red is negative, and the 
magnitudes of the dipoles are displayed on the right. 
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Figure 11. Top view of dimers formed during docking (Left) and schematic representation 
(Right) with Py in gray and Im in white. The DNA has been removed so that preferred staggered 
conformations can be viewed. From top to bottom, the dimers come from f-PyPyIm in complex 
with 5’-d(GAACTAGTTC)-3’, f-ImPyPy in complex with 5’-d(GAATGCATTC)-3’ and f-
ImPyIm in complex with 5’-d(GAACGCGTTC)-3’. Notice the spacing of the dimers.  
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Figure 12. Two-dimensional illustration of f-PyPyIm in complex with cognate sequence 5’-
d(GAACTAGTTC)-3’. Hydrogen bonds are displayed by dashed lined with respective distances. 
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Figure 13. Two-dimensional illustration of f-ImPyPy in complex with cognate sequence 5’-
d(GAATGCATTC)-3’. Hydrogen bonds are displayed by dashed lined with respective distances. 
 
f-ImPyPy/5’-d(GAATGCATTC)-3’ 
3.3 Å
3.5 Å
3.0Å
2.6 Å
3.3 Å
2.4 Å
3.6 Å
2.8 Å
2.5 Å
3.0 Å
2.9 Å
3.3 Å
+
+
 164 
 
 
Figure 14. Two-dimensional illustration of f-ImPyIm in complex with cognate sequence 5’-
d(GAACGCGTTC)-3’. Hydrogen bonds are displayed by dashed lined with respective distances. 
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Appendix A 
Supplemental Table 1. Compounds employed for training and testing. 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
A 1-deazaadenosine  45.4 -24.8 (1) 
A 1-deazapurine  131 -22.2 Aldrich 
A 2,6-diaminopurine-2'-d-riboside  4.44 -30.6 
MP 
Biomedicals 
A 2-chloro-adenosine  9.65 -28.6 
TriLink 
Biotech 
A 
 
7.5 -29.3 (10) 
A 2'-deoxyadenosine  0.23 -37.9 Sigma 
A 2'-deoxyinosine  165 -21.6 Sigma 
A 2-hydroxy-6-aminopurine  9.7 -28.6 Acros 
A 2-nitoradenosine  81 -23.4 (1) 
A 3-deaza-adenosine  0.29 -37.3 Sigma 
A 6-chloropurine riboside  15.4 -27.5 
TriLink 
Biotech 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
A 8-azidoadenosine  331 -19.9 (8) 
A 8-bromoadenosine  37.8 -25.2 Acros 
A 9-deazaadenosine  12.2 -28 (7) 
A adenine  0.3 -37.2 Sigma 
A adenosine  0.92 -34.5 Sigma 
A allopurinol  255 -20.5 Sigma 
A DAPI 0.47 -36.1 Fluka 
A DB1208 
 
0.37 -36.7 (5) 
A DB1464 
 
0.15 -39 (5) 
A Dilazep 150 -21.8 Sigma 
A Dipyridamole 51.6 -24.5 Sigma 
A formycin A 36.5 -25.3 (8) 
A Hypoxanthine 500 -18.8 Sigma 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
A 
 
9 -28.8 (1) 
A 
 
19.9 -26.8 (1) 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
A 
 
74.5 -23.6 Sigma 
A Nebularine (purine riboside) 17.1 -27.2 Sigma 
A Oxypurinol 303 -20.1 Sigma 
A Purine 18.1 -27.1 Sigma 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
A 
 
16.2 -27.3 (3) 
A 
 
9.7 -28.6 (3) 
A Tubercidin (7-deazaadenosine) 3.81 -30.9 Fluka 
A 
 
8.2 -29 (6) 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
A 
 
125 -22.3 (6) 
A Xanthine 106 -22.7 Sigma 
B 2-hydroxybenzamidine 2030 -15.4 Acros 
B 3-aminobenzamidine 722 -17.9 Acros 
B 4-aminobenzamidine 22.9 -26.5 Acros 
B Benzamidine 111 -22.6 Sigma 
B furamidine    
 
1.19 -33.8 (5) 
B DB103 
 
31.4 -25.7 (5) 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
B DB1061 
 
7.07 -29.4 (5) 
B DB1064 
 
33.2 -25.6 (5) 
B DB1111 
 
5.5 -30 (5) 
B DB1138 
 
8.1 -29.1 (5) 
B DB1213 
 
1.09 -34 (5) 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
B DB1339 
 
25 -26.3 (5) 
B DB1680 
 
0.95 -34.4 (5) 
B DB244 
 
3.23 -31.3 (5) 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
B DB249 
 
4.49 -30.5 (5) 
B DB320 
 
0.39 -36.6 (5) 
B DB544 
 
3.02 -31.5 (5) 
B DB60 
 
13.8 -27.7 (5) 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) (G
0
) (kJ/mol) Source Scaffold 
B DB607 
 
4.1 -30.8 (5) 
B DB629 
 
0.88 -34.6 (5) 
B DB686 
 
5.4 -30.1 (5) 
B DB820 
 
1.95 -32.6 (5) 
B DB829 
 
1.4 -33.4 (5) 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) (G
0
) (kJ/mol) Source Scaffold 
B DB867 
 
4 -30.8 (5) 
B DB931 
 
1.23 -33.7 (5) 
B Distamycin A 10.6 -28.4 Sigma  
B 
 
1.36 -33.5 (9) 
B 
 
0.92 -34.5 (9) 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
B 
 
3.92 -30.9 (9) 
C 
 
8.05 -29.1  (12) 
C 
 
0.38 -36.6  (12) 
C 
 
0.81 -34.8  (12) 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
C 
 
0.21 -38.1 (12)  
C 
 
1.01 -34.2 (12)  
C 
 
1.57 -33.1  (12) 
C 
 
11.9 -28.1 (13)  
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
C 
 
59.3 -24.1  (13)  
C 
 
5.8 -29.9 (10) 
C 2-aminopyridine 14.3 -27.7 Aldrich 
C 4,6-diaminopyrimidine 3.22 -31.3 Aldrich 
C 4-aminopyridine 145 -21.9 Aldrich 
C 4-aminopyrimidine 137 -22.1 Acros 
C 4-hydroxybenzamidine 235 -20.7 Aldrich 
C butamidine 1.04 -34.2 (2) 
C stilbamidine 2.42 -32.1 
Sanofi-
Aventis 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
D 
 
0.33 -37 (14)  
D 
 
129 -22.2  (14)  
D 
 
53.4 -24.4  (14)  
D 
 
4.6 -30.5 (14)   
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
D 
 
404 -19.4 (14)   
D 
 
13.1 -27.9  (14)  
D 
 
3.65 -31  (14)  
D 
 
1.58 -33.1 (14)   
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
D 
 
2.88 -31.6 (14)   
D Heptamidine 0.28 -37.4 (2) 
D Hexamidine 0.43 -36.3 (2) 
D iodo-pentamidine 0.27 -37.5 (4) 
D Megazol 192 -21.2  (15)  
D Octamidine 0.48 -36.1 (2) 
D Pentamidine 0.37 -36.7 Sigma 
D Propamidine 1.92 -32.6 (11) 
E 1,1'-(nonane-1,9-diyl)diguanidine 
 
45.4 -24.8 Biomol 
E 
 
200 -21.1 (9) 
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
E 
 
3.25 -31.3 (9) 
E 
 
8.75 -28.9 (9) 
F 
 
9.3 -28.7  (12)  
F 
 
0.38 -36.6  (13)  
F 
 
0.38 -36.6  (12)  
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Supplemental Table 1 (continued) 
Scaffold Compound Ki   of P2 (µM) 
(G
0
) 
(kJ/mol)
Source 
F 
 
37.7 -25.3 (3) 
F melarsen oxide 9.7 -28.6 
Sanofi-
Aventis 
F Melarsoprol 0.54 -35.8 
Sanofi-
Aventis 
F Thiamine 364 -19.6 Sigma 
G Aminopterin 78.4 -23.4 Sigma 
G diminazene aceturate (berenil) 2.36 -32.1 Sigma 
G Ethidium 5.96 -29.8 Sigma 
G Isometamidium 0.21 -38.1 May & 
Baker 
(1) Gift of Professor Gerrit-Jan Koomen, University of Amsterdam; Amsterdam, The Netherlands.  
(2) Gift of Professor Alan Fairlamb, University of Dundee; Dundee, UK.  
(3) Gift of Professor Katherine Radtke-Seley, University of Maryland, Baltimore Co; Baltimore, MA, USA.  
(4) Gift of Dr Philip Blower, University of Kent at Canterbury; Canterbury, UK.  
(5) Gift of Professor David Boykin, Georgia State University; Atlanta, GE, USA.  
(6) Gift of Professor Achiel Haemers, University of Antwerp; Antwerp, Belgium.  
(7) Gift of Professor Mahmoud H. el Kouni, University of Alabama at Birmingham; Birmingham, AL, USA.  
(8) Gift of Professor Simon Jarvis, University of Westminster; London, UK.  
(9) Gift of Dr Paul O’Neil, University of Liverpool; Liverpool, UK.  
(10) Gift of Professor Richard Tidwell, University of North Carolina, Chapel Hill; NC, USA.  
(11) Gift from Dr Christophe Dardonville, Instituto de Química Médica; Madrid, Spain.  
(12) Gift from Professor Ian Gilbert, University of Dundee, UK; see Stewart et al. (2005) Antimicrob. Ag. Chemother. 49, 5169-5171.  
(13) Gift from Professor Ian Gilbert, University of Dundee, UK; see Tye et al (1998) Bioorg Med Chem Lett 8, 811-816 and Klenke et al. (2001) J. Med. Chem. 44, 3440-3352.  
(14) Gift from Professor Ian Gilbert, University of Dundee, UK; see Stewart et al (2004) Antimicrob. Ag. Chemother. 48, 1733-1738 and Baliani et al (2005) J. Med. Chem. 48, 5570-5579.  
(15) Gift from Professor Bernard Bouteille, Institut d’Epidémiologie Neurologique et de Neurologie Tropicale, Limoges, France.  
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Supplemental Table 2. Listing of K
i 
values, Gibbs free energy ΔG
0 
and energy gain/loss relative to a control compound for some of the 
compounds utilised in this study and listed in Supplemental Table 1. Conclusions drawn from the data with respect to substrate 
binding of the P2 transporter are listed in the final column. 
Compound Ki value (μM) Δ(G0) 
(KJ/mol) 
δ(Δ(G0)) 
(KJ/mol) 
Relative to Conclusion 
Adenosine 0.92 ± 0.06 34.5 
 
N/A 
 
      
Position 1 
    
Average contribution of 7.7 kJ/mol to 
binding the purine ring. 
1-Deazaadenosine 45.4 ± 8.7 24.8 9.7 Adenosine 
N1 contributes of 9.7 kJ/mol to binding 
of adenosine. 
1-Deazapurine 181 ± 33 21.4 5.7 Purine 
N1 contributes of 5.7 kJ/mol to binding 
of adenine. 
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Supplemental Table 2 (continued) 
Compound Ki value (μM) Δ(G0) 
(KJ/mol) 
δ(Δ(G0)) 
(KJ/mol) 
Relative to Conclusion 
Position 2 
    
Depending on the group, substitutions 
on position reduce binding energy of 
adenosine analogs with 5 – 11 kJ/mol. 
2-Nitroadenosine 81 ± 22 23.4 11.1 Adenosine 
 
2-Hydroxy-6-aminopurine 9.7 ± 2.3 28.6 8.7 Adenine 
 
2,6-Diamino, 2’deoxypurine 
riboside 
4.4 ± 1.3 30.5 7.4 2’-Deoxyadenosine 
 
2-Chloroadenosine 9.7 ± 3.4 28.6 5.9 Adenosine 
 
      
Position 3 
    
N3 does not contribute to binding. Its 
removal re-distributes charge around 
the molecule, resulting in a slightly 
higher affinity. 
3-deazaadenosine 0.29 ± 0.06 37.3 -2.8 Adenosine 
 
      
Position 6 
    
The 6-NH2 group contributes an 
average of 8.2 kJ/mol to binding of 
aminopurines. 
6-chloropurine riboside 15.4 ± 0.8 27.5 7.0 Adenosine 
 
Purine 18.1 ± 3.2 27.1 10.2 Adenine 
 
Purine riboside 17.1 ± 2.1 27.2 7.3 Adenosine 
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Supplemental Table 2 (continued) 
Compound Ki value (μM) Δ(G0) 
(KJ/mol) 
δ(Δ(G0)) 
(KJ/mol) 
Relative to Conclusion 
Positions 6 and 1 
    
The binding energies of positions 1 and 
6 are additive, resulting in very low 
affinity for inosine and guanosine, and 
is estimated at 15.7 kJ/mol. 
Guanosine >500 
    
Inosine >500 
    
2’-deoxyinosine 165 ± 23 21.6 16.3 2’-Deoxyadenosine 
 
1-deazapurine 131 ± 34 22.2 15.1 Adenine 
 
      
Positions 6 and 2 
    
Loss of affinity can be attributed solely 
to the substitution on position 2 (see 
above). The single substitution at the 6-
amine position is therefore not (greatly) 
detrimental to binding, especially when 
the substitution is small or flexible. 
 
21 ± 9.2 
 
8.6 Adenosine 
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Supplemental Table 2 (continued) 
Compound Ki value (μM) Δ(G0) 
(KJ/mol) 
δ(Δ(G0)) 
(KJ/mol) 
Relative to Conclusion 
 
9.0 ± 1.7 
 
5.7 Adenosine 
 
      
Position 7 
    
Small apparent contribution to binding 
from N7, though too small to represent 
a full hydrogen bond. The absence of 
N7, however, decreases the positive 
charge on N9. 
7-deazaadenosine (tubercidin) 3.8 ± 0.7 30.9 3.6 Adenosine 
 
Formycin A 36.5 ± 6.6 25.3 9.2 Adenosine 
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Supplemental Table 2 (continued) 
Compound Ki value (μM) Δ(G0) 
(KJ/mol) 
δ(Δ(G0)) 
(KJ/mol) 
Relative to Conclusion 
Position 8 
    
Substitutions at position 8 are 
detrimental to binding. 
8-azidoadenosine 331 ± 142 19.9 14.6 Adenosine 
 
8-bromoadenosine 37.8 ± 8.2 25.2 9.2 Adenosine 
 
      
Position 9 
    
Significant contribution of N9 to 
adenosine binding. 
9-deazaadenosine 12.1 ± 3.2 28.1 6.4 Adenosine 
 
      
Ribose 
    
Absence of the ribose or of just the 2’-
hydroxyl group increases affinity by 
approximately 3 kJ/mol. 
Adenine 0.30 ± 0.02 37.3 -2.8 Adenosine 
 
2’-deoxyadenosine 0.23 ± 0.04 37.9 -3.4 Adenosine 
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Supplemental Table 2 (continued) 
Compound Ki value (μM) Δ(G0) 
(KJ/mol) 
δ(Δ(G0)) 
(KJ/mol) 
Relative to Conclusion 
Aromaticity 
    
The aromaticity of the purines and 
diamidines contributes importantly to 
their high affinity binding of P2, as non-
aromatic diamidines or diguanidines of 
similar length and flexibility as the 
aromatic diamidines display ~100-fold 
less affinity, corresponding to 10-11 
kJ/mol in binding energy. Presumably 
π−π-bonds with aromatic amino acid 
residues are involved in substrate-
transporter interactions. 
 
>200 
    
 
45 ± 15 24.7 11.9 Pentamidine 
 
Pentamidine 0.37 ± 0.04 36.7 
   
Propamidine 1.9 ± 0.8 32.6 
   
Stilbamidine 2.4 ± 0.3 32.0 
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Supplemental Figure 1. Initial alignments for datasets E, F and G. 
        
Dataset E
Dataset F
Dataset G
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Appendix B 
Supplemental Table 3. Training dataset of compounds with experimentally determined inhibition (IC50) values against L. donovani 
(LD) and L. amazonensis (LA). 
Name Structure LD LA 
DB667 
 
1.6 ± 0.4 0.53 ± 0.19 
DB702 
 
0.67 ± 0.14 0.29 ± 0.13 
DB709 
 
0.53 ± 0.19 0.37 ± 0.15 
DB745 
 
0.50 ± 0.15 0.12 ± 0.02 
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Supplemental Table 3 (continued) 
Name Structure LD LA 
DB750 
 
1.50 ± 0.13 0.96 ± 0.33 
DB766 
 
0.50 ± 0.10 0.087 ± .015 
DB780 
 
4.5 ± 0.9 0.51 ± 0.09 
DB894 
 
1.2 ± 0.1 0.62 ± 0.20 
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Supplemental Table 3 (continued) 
Name Structure LD LA 
DB946 
 
0.37 ± 0.04 0.11 ± 0.03 
DB1831 
 
0.55 ± 0.17 0.70 ± 0.16 
DB1848 
 
31 ± 7 5.0 ± 1.5 
DB1850 
 
1.4 ± 0.4 0.17 ± 0.06 
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Supplemental Table 3 (continued) 
Name Structure LD LA 
DB1851 
 
>50 >10 
DB1852 
 
1.4 ± 0.2 0.17 ± 0.06 
DB1853 
 
1.5 ± 0.3 0.21 ± 0.07 
DB1855 
 
20 ± 6 3.7 ± 3.2 
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Supplemental Table 3 (continued) 
Name Structure LD LA 
DB1858 
 
16 ± 4 0.90 ± 0.07 
DB1859 
 
>100 >10 
DB1860 
 
>100 >10 
DB1861 
 
>100 >10 
DB1862 
 
1.1 ± 0.4 0.25 ± 0.04 
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Supplemental Table 3 (continued) 
Name Structure LD LA 
DB1863 
 
2.5 ± 0.2 0.59 ± 0.08 
DB1867 
 
0.68 ± 1.8 0.045 ± 0.011 
DB1868 
 
1.0 ± 0.1 0.13 ± 0.07 
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Supplemental Table 3 (continued) 
Name Structure LD LA 
DB1875 
 
28 ± 4 >10 
DB1876 
 
28 ± 4 2.1 ± 0.9 
DB1880 
 
59 ± 9 > 10 
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Supplemental Table 3 (continued) 
Name Structure LD LA 
DB1888 
 
>100 >10 
DB1889 
 
>100 >10 
DB1890 
 
1.1 ± 0.2 0.095 ± 0.018 
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Supplemental Table 3 (continued) 
Name Structure LD LA 
DB1906 
 
1.9 ± 0.5 0.27 ± 0.04 
DB1907 
 
4.5 ± 0.2 2.7 ± 0.7 
DB1909 
 
23 ± 4 >10 
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Supplemental Table 3 (continued) 
Name Structure LD LA 
DB1913 
 
>50 >10 
DB1920 
 
2.4 ± 0.6 0.49 ± 0.08 
DB1921 
 
41 ± 3 4.7 ± 0.7 
 
 202 
 
Supplemental Table 3 (continued) 
Name Structure LD LA 
DB1937 
 
1.1 ± 0.2 1.1 ± 0.1 
DB1938 
 
21 ± 2 1.7 ± 0.4 
DB1939 
 
>100 0.22 ± 0.02 
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Supplemental Table 3 (continued) 
Name Structure LD LA 
DB1940 
 
0.82 ± 0.10 0.64 ± 0.19 
DB1942 
 
3.6 ± 1.1 0.81 ± 0.20 
DB1943 
 
1.3 ± 0.3 0.30 ± 0.10 
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Supplemental Table 3 (continued) 
Name Structure LD LA 
DB1950 
 
5.1 ± 1.2 >10 
DB1951 
 
28 ± 2 >10 
DB1952 
 
7.9 ± 1.5 0.32 ± 0.07 
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Appendix C 
Supplemental Table 4. Compounds with experimentally determined inhibition (IC50) values against Trypanosoma cruzi. 
No. ID Compound 4°C 37°C 
1 1MAA119 
 
32 2.3 
2 6SMB038 
 
400 19 
3 9SMB070 
 
229.3 20.9 
4 10SAB031 
 
32 32 
5 10SAB055 
 
91.6 32 
6 10SAB092 
 
32 32 
7 11SAB003 
 
400 2.7 
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Supplemental Table 4 (continued) 
No. ID Compound 4°C 37°C 
8 12SMB032 
 
32 32 
9 14SMB013 
 
32 9.3 
10 16SAB065 
 
400 32 
11 18SMB092 
 
32 32 
12 18SMB096 
 
32 32 
13 21DAP023 
 
128.6 0.7 
14 21DAP027 
 
400 32 
15 24SMB001 
 
128.6 1 
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Supplemental Table 4 (continued) 
No. ID Compound 4°C 37°C 
16 25DAP009 
 
400 1.9 
17 25DAP013 
 
32 6.1 
18 27DAP060 
 
135.8 16.3 
19 27DAP080 
 
400 32 
20 150OXD049 
 
32 32 
21 DB613A 
 
1.96 4.05 
22 DB702 
 
1.18 0.45 
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Supplemental Table 4 (continued) 
No. ID Compound 4°C 37°C 
23 DB711 
 
32 19.4 
24 DB766 
 
0.11 0.06 
25 DB786 
 
32 0.015 
26 DB824 
 
15.54 4.43 
27 DB889 
 
0.97 0.09 
28 DB1080 
 
1.77 0.24 
29 DB1195 
 
1.21 0.26 
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Supplemental Table 4 (continued) 
No. ID Compound 4°C 37°C 
30 DB1196 
 
0.81 1.19 
31 DB1201 
 
6.6 1.77 
32 DB1345 
 
3.72 0.91 
33 DB1362 
 
7 6.6 
34 DB1582 
 
32 6 
35 DB1627 
 
32 32 
36 DB1645 
 
32 0.15 
37 DB1646 
 
32 31 
38 DB1651 
 
32 6.9 
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Supplemental Table 4 (continued) 
No. ID Compound 4°C 37°C 
39 DB1670 
 
32 32 
40 DB1831 
 
0.08 0.02 
41 DB1850 
 
2.35 0.19 
42 DB1852 
 
32 0.06 
43 DB1853 
 
0.14 0.07 
44 DB1862 
 
0.79 0.06 
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Supplemental Table 4 (continued) 
No. ID Compound 4°C 37°C 
45 DB1867 
 
0.7 0.02 
46 DB1868 
 
0.28 0.06 
47 DB1890 
 
32 0.01 
 
